BEGIN:VCALENDAR
VERSION:2.0
PRODID:-//AssetMemo//Readout calendar//EN
CALSCALE:GREGORIAN
METHOD:PUBLISH
X-WR-CALNAME:Methotrexate readouts · AssetMemo
X-WR-CALDESC:Upcoming readouts of Methotrexate\, from ClinicalTrials.gov es
 timates.
REFRESH-INTERVAL;VALUE=DURATION:PT12H
X-PUBLISHED-TTL:PT12H
BEGIN:VEVENT
UID:NCT06901999-3826@assetmemo.bio
DTSTAMP:20261121T004007Z
DTSTART;VALUE=DATE:20261130
DTEND;VALUE=DATE:20261201
SUMMARY:Methotrexate: Phase 2 readout est. (NCT06901999)
DESCRIPTION:Methotrexate\, phase 2.\nStudy: Methotrexate or Thiotepa Combin
 ed With R-CHOP and Orelabrutinib in CNSL Patients\nEstimated primary compl
 etion: November 2026. This is a ClinicalTrials.gov estimate\, not a confir
 med readout date\, and it can move.\nDrug page: https://assetmemo.bio/drug
 /methotrexate#upcoming-events\nRegistry record: https://clinicaltrials.gov
 /study/NCT06901999
URL:https://assetmemo.bio/drug/methotrexate#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT03121014-3826@assetmemo.bio
DTSTAMP:20261121T004007Z
DTSTART;VALUE=DATE:20261130
DTEND;VALUE=DATE:20261201
SUMMARY:Methotrexate: Phase 2 readout est. (NCT03121014)
DESCRIPTION:Methotrexate\, phase 2.\nStudy: Study of Intensity Modulated To
 tal Marrow Irradiation (IM-TMI) in Addition to Fludarabine/Busulfan Condit
 ioning for Allogeneic Transplantation in High Risk AML and Myelodysplastic
  Syndromes\nEstimated primary completion: November 2026. This is a Clinica
 lTrials.gov estimate\, not a confirmed readout date\, and it can move.\nDr
 ug page: https://assetmemo.bio/drug/methotrexate#upcoming-events\nRegistry
  record: https://clinicaltrials.gov/study/NCT03121014
URL:https://assetmemo.bio/drug/methotrexate#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT04018937-3826@assetmemo.bio
DTSTAMP:20261121T004007Z
DTSTART;VALUE=DATE:20261130
DTEND;VALUE=DATE:20261201
SUMMARY:Methotrexate: Phase 2 readout est. (NCT04018937)
DESCRIPTION:Methotrexate\, phase 2.\nStudy: Early Human Leukocyte Antigen (
 HLA) Matched Sibling Hematopoietic Stem Cell Transplantation\nEstimated pr
 imary completion: November 2026. This is a ClinicalTrials.gov estimate\, n
 ot a confirmed readout date\, and it can move.\nDrug page: https://assetme
 mo.bio/drug/methotrexate#upcoming-events\nRegistry record: https://clinica
 ltrials.gov/study/NCT04018937
URL:https://assetmemo.bio/drug/methotrexate#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06239311-3826@assetmemo.bio
DTSTAMP:20261121T004007Z
DTSTART;VALUE=DATE:20261130
DTEND;VALUE=DATE:20261201
SUMMARY:Methotrexate: Phase 3 readout est. (NCT06239311)
DESCRIPTION:Methotrexate\, phase 3.\nStudy: Efficacy and Safety of Methotre
 xate Versus Placebo in Adults With Atopic Dermatitis.\nEstimated primary c
 ompletion: November 2026. This is a ClinicalTrials.gov estimate\, not a co
 nfirmed readout date\, and it can move.\nDrug page: https://assetmemo.bio/
 drug/methotrexate#upcoming-events\nRegistry record: https://clinicaltrials
 .gov/study/NCT06239311
URL:https://assetmemo.bio/drug/methotrexate#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07937007-3826@assetmemo.bio
DTSTAMP:20261121T004007Z
DTSTART;VALUE=DATE:20261130
DTEND;VALUE=DATE:20261201
SUMMARY:Methotrexate: Phase na readout est. (NCT07937007)
DESCRIPTION:Methotrexate\, phase na.\nStudy: Vitamin D3 Versus Methotrexate
  Versus Saline Injections for Plantar Warts\nEstimated primary completion:
  November 2026. This is a ClinicalTrials.gov estimate\, not a confirmed re
 adout date\, and it can move.\nDrug page: https://assetmemo.bio/drug/metho
 trexate#upcoming-events\nRegistry record: https://clinicaltrials.gov/study
 /NCT07937007
URL:https://assetmemo.bio/drug/methotrexate#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT03020030-3826@assetmemo.bio
DTSTAMP:20261121T004007Z
DTSTART;VALUE=DATE:20261130
DTEND;VALUE=DATE:20261201
SUMMARY:Methotrexate: Phase 3 readout est. (NCT03020030)
DESCRIPTION:Methotrexate\, phase 3\, Acute Lymphoblastic Leukemia.\nStudy: 
 Treatment of Newly Diagnosed Acute Lymphoblastic Leukemia in Children and 
 Adolescents\nEstimated primary completion: 30 November 2026. This is a Cli
 nicalTrials.gov estimate\, not a confirmed readout date\, and it can move.
 \nDrug page: https://assetmemo.bio/drug/methotrexate#upcoming-events\nRegi
 stry record: https://clinicaltrials.gov/study/NCT03020030
URL:https://assetmemo.bio/drug/methotrexate#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06877455-3826@assetmemo.bio
DTSTAMP:20261121T004007Z
DTSTART;VALUE=DATE:20261130
DTEND;VALUE=DATE:20261201
SUMMARY:Methotrexate: Phase na readout est. (NCT06877455)
DESCRIPTION:Methotrexate\, phase na.\nStudy: Topical Methotrexate with Frac
 tional CO2 Laser in Treatment of Non Segmental Vitiligo\nEstimated primary
  completion: 30 November 2026. This is a ClinicalTrials.gov estimate\, not
  a confirmed readout date\, and it can move.\nDrug page: https://assetmemo
 .bio/drug/methotrexate#upcoming-events\nRegistry record: https://clinicalt
 rials.gov/study/NCT06877455
URL:https://assetmemo.bio/drug/methotrexate#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06315309-3826@assetmemo.bio
DTSTAMP:20261121T004007Z
DTSTART;VALUE=DATE:20261231
DTEND;VALUE=DATE:20270101
SUMMARY:Methotrexate: Phase 2 readout est. (NCT06315309)
DESCRIPTION:Methotrexate\, phase 2.\nStudy: Trial of 2 Step ATG for Acute G
 VHD Prevention Post Myeloablative Allogeneic Stem Cell Transplant\nEstimat
 ed primary completion: December 2026. This is a ClinicalTrials.gov estimat
 e\, not a confirmed readout date\, and it can move.\nDrug page: https://as
 setmemo.bio/drug/methotrexate#upcoming-events\nRegistry record: https://cl
 inicaltrials.gov/study/NCT06315309
URL:https://assetmemo.bio/drug/methotrexate#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT02422641-3826@assetmemo.bio
DTSTAMP:20261121T004007Z
DTSTART;VALUE=DATE:20261231
DTEND;VALUE=DATE:20270101
SUMMARY:Methotrexate: Phase 2 readout est. (NCT02422641)
DESCRIPTION:Methotrexate\, phase 2.\nStudy: Prospective Evaluation Of High-
 Dose Systemic Methotrexate In Patients With Breast Cancer And Leptomeninge
 al Metastasis\nEstimated primary completion: December 2026. This is a Clin
 icalTrials.gov estimate\, not a confirmed readout date\, and it can move.\
 nDrug page: https://assetmemo.bio/drug/methotrexate#upcoming-events\nRegis
 try record: https://clinicaltrials.gov/study/NCT02422641
URL:https://assetmemo.bio/drug/methotrexate#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT03593759-3826@assetmemo.bio
DTSTAMP:20261121T004007Z
DTSTART;VALUE=DATE:20261231
DTEND;VALUE=DATE:20270101
SUMMARY:Methotrexate: Phase 3 readout est. (NCT03593759)
DESCRIPTION:Methotrexate\, phase 3.\nStudy: Cardiac Sarcoidosis Randomized 
 Trial\nEstimated primary completion: December 2026. This is a ClinicalTria
 ls.gov estimate\, not a confirmed readout date\, and it can move.\nDrug pa
 ge: https://assetmemo.bio/drug/methotrexate#upcoming-events\nRegistry reco
 rd: https://clinicaltrials.gov/study/NCT03593759
URL:https://assetmemo.bio/drug/methotrexate#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06207123-3826@assetmemo.bio
DTSTAMP:20261121T004007Z
DTSTART;VALUE=DATE:20261201
DTEND;VALUE=DATE:20261202
SUMMARY:Methotrexate: Phase 1/2 readout est. (NCT06207123)
DESCRIPTION:Methotrexate\, phase 1/2\, Acute Lymphoblastic Leukemia.\nStudy
 : A Study to Investigate LP-118\, Ponatinib\, Vincristine and Dexamethason
 e in Relapsed/Refractory Acute Lymphoblastic Leukemia (ALL) or Lymphoblast
 ic Lymphoma (LBL)\nEstimated primary completion: 1 December 2026. This is 
 a ClinicalTrials.gov estimate\, not a confirmed readout date\, and it can 
 move.\nDrug page: https://assetmemo.bio/drug/methotrexate#upcoming-events\
 nRegistry record: https://clinicaltrials.gov/study/NCT06207123
URL:https://assetmemo.bio/drug/methotrexate#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06387121-3826@assetmemo.bio
DTSTAMP:20261121T004007Z
DTSTART;VALUE=DATE:20261201
DTEND;VALUE=DATE:20261202
SUMMARY:Methotrexate: Phase 2 readout est. (NCT06387121)
DESCRIPTION:Methotrexate\, phase 2.\nStudy: Efficacy and Safety of Low-dose
  Chemotherapy Plus Immuno-targeted Drugs in Newly Diagnosed Adult Ph- B-AL
 L\nEstimated primary completion: 1 December 2026. This is a ClinicalTrials
 .gov estimate\, not a confirmed readout date\, and it can move.\nDrug page
 : https://assetmemo.bio/drug/methotrexate#upcoming-events\nRegistry record
 : https://clinicaltrials.gov/study/NCT06387121
URL:https://assetmemo.bio/drug/methotrexate#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07581418-3826@assetmemo.bio
DTSTAMP:20261121T004007Z
DTSTART;VALUE=DATE:20261201
DTEND;VALUE=DATE:20261202
SUMMARY:Methotrexate: Phase na readout est. (NCT07581418)
DESCRIPTION:Methotrexate\, phase na.\nStudy: Comparison of Methotrexate and
  Tofacitinib in Chronic Plaque Psoriasis\nEstimated primary completion: 1 
 December 2026. This is a ClinicalTrials.gov estimate\, not a confirmed rea
 dout date\, and it can move.\nDrug page: https://assetmemo.bio/drug/methot
 rexate#upcoming-events\nRegistry record: https://clinicaltrials.gov/study/
 NCT07581418
URL:https://assetmemo.bio/drug/methotrexate#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06543992-3826@assetmemo.bio
DTSTAMP:20261121T004007Z
DTSTART;VALUE=DATE:20261213
DTEND;VALUE=DATE:20261214
SUMMARY:Methotrexate: Phase 2 readout est. (NCT06543992)
DESCRIPTION:Methotrexate\, phase 2.\nStudy: Efficacy and Safety of Intrathe
 cal Administration of Thiotepa in Combination With Methotrexate in Breast 
 Cancer With Leptomeningeal Metastasis\nEstimated primary completion: 13 De
 cember 2026. This is a ClinicalTrials.gov estimate\, not a confirmed reado
 ut date\, and it can move.\nDrug page: https://assetmemo.bio/drug/methotre
 xate#upcoming-events\nRegistry record: https://clinicaltrials.gov/study/NC
 T06543992
URL:https://assetmemo.bio/drug/methotrexate#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06298071-3826@assetmemo.bio
DTSTAMP:20261121T004007Z
DTSTART;VALUE=DATE:20261230
DTEND;VALUE=DATE:20261231
SUMMARY:Methotrexate: Phase 1 readout est. (NCT06298071)
DESCRIPTION:Methotrexate\, phase 1.\nStudy: A Phase Ib Clinical Trial of Pe
 guricase for Injection With Methotrexate in Patients With Uncontrolled Gou
 t.\nEstimated primary completion: 30 December 2026. This is a ClinicalTria
 ls.gov estimate\, not a confirmed readout date\, and it can move.\nDrug pa
 ge: https://assetmemo.bio/drug/methotrexate#upcoming-events\nRegistry reco
 rd: https://clinicaltrials.gov/study/NCT06298071
URL:https://assetmemo.bio/drug/methotrexate#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06475235-3826@assetmemo.bio
DTSTAMP:20261121T004007Z
DTSTART;VALUE=DATE:20261230
DTEND;VALUE=DATE:20261231
SUMMARY:Methotrexate: Phase 1 readout est. (NCT06475235)
DESCRIPTION:Methotrexate\, phase 1.\nStudy: Pembrolizumab + Chemotherapy in
  Newly Diagnosed PCNSL\nEstimated primary completion: 30 December 2026. Th
 is is a ClinicalTrials.gov estimate\, not a confirmed readout date\, and i
 t can move.\nDrug page: https://assetmemo.bio/drug/methotrexate#upcoming-e
 vents\nRegistry record: https://clinicaltrials.gov/study/NCT06475235
URL:https://assetmemo.bio/drug/methotrexate#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT05257018-3826@assetmemo.bio
DTSTAMP:20261121T004007Z
DTSTART;VALUE=DATE:20261230
DTEND;VALUE=DATE:20261231
SUMMARY:Methotrexate: Phase 2 readout est. (NCT05257018)
DESCRIPTION:Methotrexate\, phase 2.\nStudy: R-CDOP Combined With Intratheca
 l Methotrexate for DLBCL Patients With High-risk of CNS Relapse\nEstimated
  primary completion: 30 December 2026. This is a ClinicalTrials.gov estima
 te\, not a confirmed readout date\, and it can move.\nDrug page: https://a
 ssetmemo.bio/drug/methotrexate#upcoming-events\nRegistry record: https://c
 linicaltrials.gov/study/NCT05257018
URL:https://assetmemo.bio/drug/methotrexate#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07559097-3826@assetmemo.bio
DTSTAMP:20261121T004007Z
DTSTART;VALUE=DATE:20261231
DTEND;VALUE=DATE:20270101
SUMMARY:Methotrexate: Phase 1/2 readout est. (NCT07559097)
DESCRIPTION:Methotrexate\, phase 1/2.\nStudy: Exploration of the Applicatio
 n of Methotrexate-loaded Drug Vesicles in Intrathecal Injection for Mening
 eal Metastasis of Lung Cancer\nEstimated primary completion: 31 December 2
 026. This is a ClinicalTrials.gov estimate\, not a confirmed readout date\
 , and it can move.\nDrug page: https://assetmemo.bio/drug/methotrexate#upc
 oming-events\nRegistry record: https://clinicaltrials.gov/study/NCT0755909
 7
URL:https://assetmemo.bio/drug/methotrexate#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT04216524-3826@assetmemo.bio
DTSTAMP:20261121T004007Z
DTSTART;VALUE=DATE:20261231
DTEND;VALUE=DATE:20270101
SUMMARY:Methotrexate: Phase 2 readout est. (NCT04216524)
DESCRIPTION:Methotrexate\, phase 2.\nStudy: Venetoclax\, SL-401\, and Chemo
 therapy for the Treatment of Blastic Plasmacytoid Dendritic Cell Neoplasm\
 nEstimated primary completion: 31 December 2026. This is a ClinicalTrials.
 gov estimate\, not a confirmed readout date\, and it can move.\nDrug page:
  https://assetmemo.bio/drug/methotrexate#upcoming-events\nRegistry record:
  https://clinicaltrials.gov/study/NCT04216524
URL:https://assetmemo.bio/drug/methotrexate#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT02981628-3826@assetmemo.bio
DTSTAMP:20261121T004007Z
DTSTART;VALUE=DATE:20261231
DTEND;VALUE=DATE:20270101
SUMMARY:Methotrexate: Phase 2 readout est. (NCT02981628)
DESCRIPTION:Methotrexate\, phase 2\, Acute Lymphoblastic Leukemia.\nStudy: 
 Inotuzumab Ozogamicin in Treating Younger Patients With B-Lymphoblastic Ly
 mphoma or Relapsed or Refractory CD22 Positive B Acute Lymphoblastic Leuke
 mia\nEstimated primary completion: 31 December 2026. This is a ClinicalTri
 als.gov estimate\, not a confirmed readout date\, and it can move.\nDrug p
 age: https://assetmemo.bio/drug/methotrexate#upcoming-events\nRegistry rec
 ord: https://clinicaltrials.gov/study/NCT02981628
URL:https://assetmemo.bio/drug/methotrexate#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT05681260-3826@assetmemo.bio
DTSTAMP:20261121T004007Z
DTSTART;VALUE=DATE:20261231
DTEND;VALUE=DATE:20270101
SUMMARY:Methotrexate: Phase 3 readout est. (NCT05681260)
DESCRIPTION:Methotrexate\, phase 3.\nStudy: Capizzi Escalating Methotrexate
  Versus High Dose Methotrexate in Children With Newly Diagnosed T-cell Lym
 phoblastic Lymphoma (T-LBL)\nEstimated primary completion: 31 December 202
 6. This is a ClinicalTrials.gov estimate\, not a confirmed readout date\, 
 and it can move.\nDrug page: https://assetmemo.bio/drug/methotrexate#upcom
 ing-events\nRegistry record: https://clinicaltrials.gov/study/NCT05681260
URL:https://assetmemo.bio/drug/methotrexate#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT05353829-3826@assetmemo.bio
DTSTAMP:20261121T004007Z
DTSTART;VALUE=DATE:20261231
DTEND;VALUE=DATE:20270101
SUMMARY:Methotrexate: Phase 4 readout est. (NCT05353829)
DESCRIPTION:Methotrexate\, phase 4\, Rheumatoid Arthritis.\nStudy: Methotre
 xate in Patients with Early Rheumatoid Arthritis\nEstimated primary comple
 tion: 31 December 2026. This is a ClinicalTrials.gov estimate\, not a conf
 irmed readout date\, and it can move.\nDrug page: https://assetmemo.bio/dr
 ug/methotrexate#upcoming-events\nRegistry record: https://clinicaltrials.g
 ov/study/NCT05353829
URL:https://assetmemo.bio/drug/methotrexate#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06177067-3826@assetmemo.bio
DTSTAMP:20261121T004007Z
DTSTART;VALUE=DATE:20270131
DTEND;VALUE=DATE:20270201
SUMMARY:Methotrexate: Phase 1 readout est. (NCT06177067)
DESCRIPTION:Methotrexate\, phase 1.\nStudy: Study of Revumenib\, Azacitidin
 e\, and Venetoclax in Pediatric and Young Adult Patients With Refractory o
 r Relapsed Acute Myeloid Leukemia\nEstimated primary completion: January 2
 027. This is a ClinicalTrials.gov estimate\, not a confirmed readout date\
 , and it can move.\nDrug page: https://assetmemo.bio/drug/methotrexate#upc
 oming-events\nRegistry record: https://clinicaltrials.gov/study/NCT0617706
 7
URL:https://assetmemo.bio/drug/methotrexate#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07352917-3826@assetmemo.bio
DTSTAMP:20261121T004007Z
DTSTART;VALUE=DATE:20270131
DTEND;VALUE=DATE:20270201
SUMMARY:Methotrexate: Phase 2 readout est. (NCT07352917)
DESCRIPTION:Methotrexate\, phase 2.\nStudy: Methotrexate for Severe Vulvar 
 Lichen Sclerosus\nEstimated primary completion: January 2027. This is a Cl
 inicalTrials.gov estimate\, not a confirmed readout date\, and it can move
 .\nDrug page: https://assetmemo.bio/drug/methotrexate#upcoming-events\nReg
 istry record: https://clinicaltrials.gov/study/NCT07352917
URL:https://assetmemo.bio/drug/methotrexate#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06590090-3826@assetmemo.bio
DTSTAMP:20261121T004007Z
DTSTART;VALUE=DATE:20270115
DTEND;VALUE=DATE:20270116
SUMMARY:Methotrexate: Phase 2 readout est. (NCT06590090)
DESCRIPTION:Methotrexate\, phase 2\, Rheumatoid Arthritis.\nStudy: Natrunix
  in Combination With Methotrexate for Rheumatoid Arthritis Treatment\nEsti
 mated primary completion: 15 January 2027. This is a ClinicalTrials.gov es
 timate\, not a confirmed readout date\, and it can move.\nDrug page: https
 ://assetmemo.bio/drug/methotrexate#upcoming-events\nRegistry record: https
 ://clinicaltrials.gov/study/NCT06590090
URL:https://assetmemo.bio/drug/methotrexate#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07288307-3826@assetmemo.bio
DTSTAMP:20261121T004007Z
DTSTART;VALUE=DATE:20270120
DTEND;VALUE=DATE:20270121
SUMMARY:Methotrexate: Phase 2 readout est. (NCT07288307)
DESCRIPTION:Methotrexate\, phase 2.\nStudy: Surgical Evacuation Versus Meth
 otrexate Injection in Treatment of Caesarean Scar Pregnancy [Clinical Tria
 l ]\nEstimated primary completion: 20 January 2027. This is a ClinicalTria
 ls.gov estimate\, not a confirmed readout date\, and it can move.\nDrug pa
 ge: https://assetmemo.bio/drug/methotrexate#upcoming-events\nRegistry reco
 rd: https://clinicaltrials.gov/study/NCT07288307
URL:https://assetmemo.bio/drug/methotrexate#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT05583071-3826@assetmemo.bio
DTSTAMP:20261121T004007Z
DTSTART;VALUE=DATE:20270228
DTEND;VALUE=DATE:20270301
SUMMARY:Methotrexate: Phase 2 readout est. (NCT05583071)
DESCRIPTION:Methotrexate\, phase 2.\nStudy: Methotrexate\, Tafasitamab\, Le
 nalidomide and Rituximab in Patients With PCNSL\nEstimated primary complet
 ion: February 2027. This is a ClinicalTrials.gov estimate\, not a confirme
 d readout date\, and it can move.\nDrug page: https://assetmemo.bio/drug/m
 ethotrexate#upcoming-events\nRegistry record: https://clinicaltrials.gov/s
 tudy/NCT05583071
URL:https://assetmemo.bio/drug/methotrexate#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT05519579-3826@assetmemo.bio
DTSTAMP:20261121T004007Z
DTSTART;VALUE=DATE:20270201
DTEND;VALUE=DATE:20270202
SUMMARY:Methotrexate: Phase 2 readout est. (NCT05519579)
DESCRIPTION:Methotrexate\, phase 2\, Acute Lymphoblastic Leukemia.\nStudy: 
 Intrathecal Chemoprophylaxis to Prevent Neurotoxicity Associated With Blin
 atumomab Therapy for Acute Lymphoblastic Leukemia\nEstimated primary compl
 etion: 1 February 2027. This is a ClinicalTrials.gov estimate\, not a conf
 irmed readout date\, and it can move.\nDrug page: https://assetmemo.bio/dr
 ug/methotrexate#upcoming-events\nRegistry record: https://clinicaltrials.g
 ov/study/NCT05519579
URL:https://assetmemo.bio/drug/methotrexate#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06832267-3826@assetmemo.bio
DTSTAMP:20261121T004007Z
DTSTART;VALUE=DATE:20270213
DTEND;VALUE=DATE:20270214
SUMMARY:Methotrexate: Phase na readout est. (NCT06832267)
DESCRIPTION:Methotrexate\, phase na.\nStudy: Rituximab-Methotrexate-Temozol
 omide-Thiotepa (RMTT) Regimen As First-line Therapy for PCNS DLBCL\nEstima
 ted primary completion: 13 February 2027. This is a ClinicalTrials.gov est
 imate\, not a confirmed readout date\, and it can move.\nDrug page: https:
 //assetmemo.bio/drug/methotrexate#upcoming-events\nRegistry record: https:
 //clinicaltrials.gov/study/NCT06832267
URL:https://assetmemo.bio/drug/methotrexate#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT03147612-3826@assetmemo.bio
DTSTAMP:20261121T004007Z
DTSTART;VALUE=DATE:20270228
DTEND;VALUE=DATE:20270301
SUMMARY:Methotrexate: Phase 2 readout est. (NCT03147612)
DESCRIPTION:Methotrexate\, phase 2\, Acute Lymphoblastic Leukemia.\nStudy: 
 Low-Intensity Chemotherapy\, Ponatinib and Blinatumomab in Treating Patien
 ts With Philadelphia Chromosome-Positive and/or BCR-ABL Positive Acute Lym
 phoblastic Leukemia\nEstimated primary completion: 28 February 2027. This 
 is a ClinicalTrials.gov estimate\, not a confirmed readout date\, and it c
 an move.\nDrug page: https://assetmemo.bio/drug/methotrexate#upcoming-even
 ts\nRegistry record: https://clinicaltrials.gov/study/NCT03147612
URL:https://assetmemo.bio/drug/methotrexate#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT04329325-3826@assetmemo.bio
DTSTAMP:20261121T004007Z
DTSTART;VALUE=DATE:20270331
DTEND;VALUE=DATE:20270401
SUMMARY:Methotrexate: Phase 2 readout est. (NCT04329325)
DESCRIPTION:Methotrexate\, phase 2\, Acute Lymphoblastic Leukemia.\nStudy: 
 Blinatumomab and Tyrosine Kinase Inhibitor Therapy in People With Philadel
 phia Chromosome-Positive Acute Lymphoblastic Leukemia\nEstimated primary c
 ompletion: March 2027. This is a ClinicalTrials.gov estimate\, not a confi
 rmed readout date\, and it can move.\nDrug page: https://assetmemo.bio/dru
 g/methotrexate#upcoming-events\nRegistry record: https://clinicaltrials.go
 v/study/NCT04329325
URL:https://assetmemo.bio/drug/methotrexate#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07636057-3826@assetmemo.bio
DTSTAMP:20261121T004007Z
DTSTART;VALUE=DATE:20270305
DTEND;VALUE=DATE:20270306
SUMMARY:Methotrexate: Phase 4 readout est. (NCT07636057)
DESCRIPTION:Methotrexate\, phase 4\, Rheumatoid Arthritis.\nStudy: Comparis
 on of Effectiveness and Safety of Tofacitinib Versus Upadacitinib as Add-o
 n to Methotrexate in Rheumatoid Arthritis\nEstimated primary completion: 5
  March 2027. This is a ClinicalTrials.gov estimate\, not a confirmed reado
 ut date\, and it can move.\nDrug page: https://assetmemo.bio/drug/methotre
 xate#upcoming-events\nRegistry record: https://clinicaltrials.gov/study/NC
 T07636057
URL:https://assetmemo.bio/drug/methotrexate#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT03710772-3826@assetmemo.bio
DTSTAMP:20261121T004007Z
DTSTART;VALUE=DATE:20270322
DTEND;VALUE=DATE:20270323
SUMMARY:Methotrexate: Phase 2 readout est. (NCT03710772)
DESCRIPTION:Methotrexate\, phase 2.\nStudy: Ibrutinib\, Rituximab\, Venetoc
 lax\, and Combination Chemotherapy in Treating Patients With Newly Diagnos
 ed Mantle Cell Lymphoma\nEstimated primary completion: 22 March 2027. This
  is a ClinicalTrials.gov estimate\, not a confirmed readout date\, and it 
 can move.\nDrug page: https://assetmemo.bio/drug/methotrexate#upcoming-eve
 nts\nRegistry record: https://clinicaltrials.gov/study/NCT03710772
URL:https://assetmemo.bio/drug/methotrexate#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07406230-3826@assetmemo.bio
DTSTAMP:20261121T004007Z
DTSTART;VALUE=DATE:20270430
DTEND;VALUE=DATE:20270501
SUMMARY:Methotrexate: Phase na readout est. (NCT07406230)
DESCRIPTION:Methotrexate\, phase na.\nStudy: Methotrexate Early Toxicity Mo
 nitoring\nEstimated primary completion: April 2027. This is a ClinicalTria
 ls.gov estimate\, not a confirmed readout date\, and it can move.\nDrug pa
 ge: https://assetmemo.bio/drug/methotrexate#upcoming-events\nRegistry reco
 rd: https://clinicaltrials.gov/study/NCT07406230
URL:https://assetmemo.bio/drug/methotrexate#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT05303792-3826@assetmemo.bio
DTSTAMP:20261121T004007Z
DTSTART;VALUE=DATE:20270401
DTEND;VALUE=DATE:20270402
SUMMARY:Methotrexate: Phase 2 readout est. (NCT05303792)
DESCRIPTION:Methotrexate\, phase 2\, Acute Lymphoblastic Leukemia.\nStudy: 
 Comparing Inotuzumab Combined With Low Intensity Chemotherapy Plus Blinatu
 momab to Usual Chemotherapy Plus Blinatumomab in Older Adults With CD22+ B
 -cell Acute Lymphoblastic Leukemia\nEstimated primary completion: 1 April 
 2027. This is a ClinicalTrials.gov estimate\, not a confirmed readout date
 \, and it can move.\nDrug page: https://assetmemo.bio/drug/methotrexate#up
 coming-events\nRegistry record: https://clinicaltrials.gov/study/NCT053037
 92
URL:https://assetmemo.bio/drug/methotrexate#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT05157971-3826@assetmemo.bio
DTSTAMP:20261121T004007Z
DTSTART;VALUE=DATE:20270412
DTEND;VALUE=DATE:20270413
SUMMARY:Methotrexate: Phase 1 readout est. (NCT05157971)
DESCRIPTION:Methotrexate\, phase 1\, Acute Lymphoblastic Leukemia.\nStudy: 
 Venetoclax and a Pediatric-Inspired Regimen for the Treatment of Newly Dia
 gnosed B Cell Acute Lymphoblastic Leukemia\nEstimated primary completion: 
 12 April 2027. This is a ClinicalTrials.gov estimate\, not a confirmed rea
 dout date\, and it can move.\nDrug page: https://assetmemo.bio/drug/methot
 rexate#upcoming-events\nRegistry record: https://clinicaltrials.gov/study/
 NCT05157971
URL:https://assetmemo.bio/drug/methotrexate#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07409103-3826@assetmemo.bio
DTSTAMP:20261121T004007Z
DTSTART;VALUE=DATE:20270415
DTEND;VALUE=DATE:20270416
SUMMARY:Methotrexate: Phase 2 readout est. (NCT07409103)
DESCRIPTION:Methotrexate\, phase 2\, Rheumatoid Arthritis.\nStudy: A Study 
 to Assess the Safety and Efficacy of Different Doses of ELV001 to Treat Ac
 tive Rheumatoid Arthritis in Patients With an Inadequate Response to Metho
 trexate and Tumor Necrosis Factor Inhibition (START SYNERGY)\nEstimated pr
 imary completion: 15 April 2027. This is a ClinicalTrials.gov estimate\, n
 ot a confirmed readout date\, and it can move.\nDrug page: https://assetme
 mo.bio/drug/methotrexate#upcoming-events\nRegistry record: https://clinica
 ltrials.gov/study/NCT07409103
URL:https://assetmemo.bio/drug/methotrexate#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06895473-3826@assetmemo.bio
DTSTAMP:20261121T004007Z
DTSTART;VALUE=DATE:20270430
DTEND;VALUE=DATE:20270501
SUMMARY:Methotrexate: Phase 2 readout est. (NCT06895473)
DESCRIPTION:Methotrexate\, phase 2.\nStudy: Intrathecal Cytarabine\, Methot
 rexate\, and Hydrocortisone for the Prevention of High-Grade Chimeric Anti
 gen Receptor T-Cell-Associated Neurotoxicity Syndrome\nEstimated primary c
 ompletion: 30 April 2027. This is a ClinicalTrials.gov estimate\, not a co
 nfirmed readout date\, and it can move.\nDrug page: https://assetmemo.bio/
 drug/methotrexate#upcoming-events\nRegistry record: https://clinicaltrials
 .gov/study/NCT06895473
URL:https://assetmemo.bio/drug/methotrexate#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06998628-3826@assetmemo.bio
DTSTAMP:20261121T004007Z
DTSTART;VALUE=DATE:20270530
DTEND;VALUE=DATE:20270531
SUMMARY:Methotrexate: Phase 2 readout est. (NCT06998628)
DESCRIPTION:Methotrexate\, phase 2\, Rheumatoid Arthritis.\nStudy: Pentoxif
 ylline as Anti-Inflammatory in Patients With Rheumatoid Arthritis\nEstimat
 ed primary completion: 30 May 2027. This is a ClinicalTrials.gov estimate\
 , not a confirmed readout date\, and it can move.\nDrug page: https://asse
 tmemo.bio/drug/methotrexate#upcoming-events\nRegistry record: https://clin
 icaltrials.gov/study/NCT06998628
URL:https://assetmemo.bio/drug/methotrexate#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06541249-3826@assetmemo.bio
DTSTAMP:20261121T004007Z
DTSTART;VALUE=DATE:20270630
DTEND;VALUE=DATE:20270701
SUMMARY:Methotrexate: Phase 2 readout est. (NCT06541249)
DESCRIPTION:Methotrexate\, phase 2.\nStudy: MethoTRExATE in MyelOpRolifErat
 ive Neoplasms (TREATMORE) Trial\nEstimated primary completion: June 2027. 
 This is a ClinicalTrials.gov estimate\, not a confirmed readout date\, and
  it can move.\nDrug page: https://assetmemo.bio/drug/methotrexate#upcoming
 -events\nRegistry record: https://clinicaltrials.gov/study/NCT06541249
URL:https://assetmemo.bio/drug/methotrexate#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07624903-3826@assetmemo.bio
DTSTAMP:20261121T004007Z
DTSTART;VALUE=DATE:20270630
DTEND;VALUE=DATE:20270701
SUMMARY:Methotrexate: Phase 2 readout est. (NCT07624903)
DESCRIPTION:Methotrexate\, phase 2.\nStudy: Letrozole Versus Methotrexate f
 or Management of Undisturbed Ectopic Pregnancy\nEstimated primary completi
 on: June 2027. This is a ClinicalTrials.gov estimate\, not a confirmed rea
 dout date\, and it can move.\nDrug page: https://assetmemo.bio/drug/methot
 rexate#upcoming-events\nRegistry record: https://clinicaltrials.gov/study/
 NCT07624903
URL:https://assetmemo.bio/drug/methotrexate#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT03206671-3826@assetmemo.bio
DTSTAMP:20261121T004007Z
DTSTART;VALUE=DATE:20270630
DTEND;VALUE=DATE:20270701
SUMMARY:Methotrexate: Phase 3 readout est. (NCT03206671)
DESCRIPTION:Methotrexate\, phase 3.\nStudy: Treatment Protocol of the NHL-B
 FM and the NOPHO Study Groups for Mature Aggressive B-cell Lymphoma and Le
 ukemia in Children and Adolescents\nEstimated primary completion: June 202
 7. This is a ClinicalTrials.gov estimate\, not a confirmed readout date\, 
 and it can move.\nDrug page: https://assetmemo.bio/drug/methotrexate#upcom
 ing-events\nRegistry record: https://clinicaltrials.gov/study/NCT03206671
URL:https://assetmemo.bio/drug/methotrexate#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06649136-3826@assetmemo.bio
DTSTAMP:20261121T004007Z
DTSTART;VALUE=DATE:20270607
DTEND;VALUE=DATE:20270608
SUMMARY:Methotrexate: Phase 4 readout est. (NCT06649136)
DESCRIPTION:Methotrexate\, phase 4\, Rheumatoid Arthritis.\nStudy: MethMax 
 Trial: MAXimising the METHotrexate Therapy Potential in Patients With Acti
 ve Rheumatoid Arthritis\nEstimated primary completion: 7 June 2027. This i
 s a ClinicalTrials.gov estimate\, not a confirmed readout date\, and it ca
 n move.\nDrug page: https://assetmemo.bio/drug/methotrexate#upcoming-event
 s\nRegistry record: https://clinicaltrials.gov/study/NCT06649136
URL:https://assetmemo.bio/drug/methotrexate#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT02427620-3826@assetmemo.bio
DTSTAMP:20261121T004007Z
DTSTART;VALUE=DATE:20270630
DTEND;VALUE=DATE:20270701
SUMMARY:Methotrexate: Phase 2 readout est. (NCT02427620)
DESCRIPTION:Methotrexate\, phase 2.\nStudy: Ibrutinib\, Rituximab\, and Con
 solidation Chemotherapy in Treating Young Patients With Newly Diagnosed Ma
 ntle Cell Lymphoma\nEstimated primary completion: 30 June 2027. This is a 
 ClinicalTrials.gov estimate\, not a confirmed readout date\, and it can mo
 ve.\nDrug page: https://assetmemo.bio/drug/methotrexate#upcoming-events\nR
 egistry record: https://clinicaltrials.gov/study/NCT02427620
URL:https://assetmemo.bio/drug/methotrexate#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06941376-3826@assetmemo.bio
DTSTAMP:20261121T004007Z
DTSTART;VALUE=DATE:20270731
DTEND;VALUE=DATE:20270801
SUMMARY:Methotrexate: Phase 2 readout est. (NCT06941376)
DESCRIPTION:Methotrexate\, phase 2.\nStudy: Pragmatic\, Open-Label Study to
  Pilot Evaluation for Clinical Trials in Relapsing Polychondritis\nEstimat
 ed primary completion: July 2027. This is a ClinicalTrials.gov estimate\, 
 not a confirmed readout date\, and it can move.\nDrug page: https://assetm
 emo.bio/drug/methotrexate#upcoming-events\nRegistry record: https://clinic
 altrials.gov/study/NCT06941376
URL:https://assetmemo.bio/drug/methotrexate#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT05303727-3826@assetmemo.bio
DTSTAMP:20261121T004007Z
DTSTART;VALUE=DATE:20270831
DTEND;VALUE=DATE:20270901
SUMMARY:Methotrexate: Phase 2 readout est. (NCT05303727)
DESCRIPTION:Methotrexate\, phase 2.\nStudy: Allogeneic Hematopoietic Stem C
 ell Transplantation for 4/M Neuroblastoma\nEstimated primary completion: A
 ugust 2027. This is a ClinicalTrials.gov estimate\, not a confirmed readou
 t date\, and it can move.\nDrug page: https://assetmemo.bio/drug/methotrex
 ate#upcoming-events\nRegistry record: https://clinicaltrials.gov/study/NCT
 05303727
URL:https://assetmemo.bio/drug/methotrexate#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT01920737-3826@assetmemo.bio
DTSTAMP:20261121T004007Z
DTSTART;VALUE=DATE:20270831
DTEND;VALUE=DATE:20270901
SUMMARY:Methotrexate: Phase 2 readout est. (NCT01920737)
DESCRIPTION:Methotrexate\, phase 2\, Acute Lymphoblastic Leukemia.\nStudy: 
 A Novel "Pediatric-Inspired" Regimen With Reduced Myelosuppressive Drugs f
 or Adults (Aged 18-60) With Newly Diagnosed Ph Negative Acute Lymphoblasti
 c Leukemia\nEstimated primary completion: August 2027. This is a ClinicalT
 rials.gov estimate\, not a confirmed readout date\, and it can move.\nDrug
  page: https://assetmemo.bio/drug/methotrexate#upcoming-events\nRegistry r
 ecord: https://clinicaltrials.gov/study/NCT01920737
URL:https://assetmemo.bio/drug/methotrexate#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT04609046-3826@assetmemo.bio
DTSTAMP:20261121T004007Z
DTSTART;VALUE=DATE:20270801
DTEND;VALUE=DATE:20270802
SUMMARY:Methotrexate: Phase 1 readout est. (NCT04609046)
DESCRIPTION:Methotrexate\, phase 1.\nStudy: Testing the Addition of Lenalid
 omide and Nivolumab to the Usual Treatment for Primary CNS Lymphoma\nEstim
 ated primary completion: 1 August 2027. This is a ClinicalTrials.gov estim
 ate\, not a confirmed readout date\, and it can move.\nDrug page: https://
 assetmemo.bio/drug/methotrexate#upcoming-events\nRegistry record: https://
 clinicaltrials.gov/study/NCT04609046
URL:https://assetmemo.bio/drug/methotrexate#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT04483466-3826@assetmemo.bio
DTSTAMP:20261121T004007Z
DTSTART;VALUE=DATE:20270830
DTEND;VALUE=DATE:20270831
SUMMARY:Methotrexate: Phase 3 readout est. (NCT04483466)
DESCRIPTION:Methotrexate\, phase 3.\nStudy: Methotrexate Treatment of Arthr
 itis Caused by Chikungunya Virus (MARCH)\nEstimated primary completion: 30
  August 2027. This is a ClinicalTrials.gov estimate\, not a confirmed read
 out date\, and it can move.\nDrug page: https://assetmemo.bio/drug/methotr
 exate#upcoming-events\nRegistry record: https://clinicaltrials.gov/study/N
 CT04483466
URL:https://assetmemo.bio/drug/methotrexate#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07191431-3826@assetmemo.bio
DTSTAMP:20261121T004007Z
DTSTART;VALUE=DATE:20270902
DTEND;VALUE=DATE:20270903
SUMMARY:Methotrexate: Phase na readout est. (NCT07191431)
DESCRIPTION:Methotrexate\, phase na.\nStudy: A Clinical Study on the Effica
 cy and Safety of Methotrexate (MTX) or Thiotepa (for MTX Intolerance) or T
 emozolomide (TMZ) Combined With Orelabrutinib and Selinexor in Relapsed/Re
 fractory Primary or Secondary Central Nervous System Lymphoma（SELINA）\
 nEstimated primary completion: 2 September 2027. This is a ClinicalTrials.
 gov estimate\, not a confirmed readout date\, and it can move.\nDrug page:
  https://assetmemo.bio/drug/methotrexate#upcoming-events\nRegistry record:
  https://clinicaltrials.gov/study/NCT07191431
URL:https://assetmemo.bio/drug/methotrexate#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT04628767-3826@assetmemo.bio
DTSTAMP:20261121T004007Z
DTSTART;VALUE=DATE:20270930
DTEND;VALUE=DATE:20271001
SUMMARY:Methotrexate: Phase 2/3 readout est. (NCT04628767)
DESCRIPTION:Methotrexate\, phase 2/3.\nStudy: Testing the Addition of MEDI4
 736 (Durvalumab) to Chemotherapy Before Surgery for Patients With High-Gra
 de Upper Urinary Tract Cancer\nEstimated primary completion: 30 September 
 2027. This is a ClinicalTrials.gov estimate\, not a confirmed readout date
 \, and it can move.\nDrug page: https://assetmemo.bio/drug/methotrexate#up
 coming-events\nRegistry record: https://clinicaltrials.gov/study/NCT046287
 67
URL:https://assetmemo.bio/drug/methotrexate#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT03914625-3826@assetmemo.bio
DTSTAMP:20261121T004007Z
DTSTART;VALUE=DATE:20270930
DTEND;VALUE=DATE:20271001
SUMMARY:Methotrexate: Phase 3 readout est. (NCT03914625)
DESCRIPTION:Methotrexate\, phase 3\, Acute Lymphoblastic Leukemia.\nStudy: 
 A Study to Investigate Blinatumomab in Combination With Chemotherapy in Pa
 tients With Newly Diagnosed B-Lymphoblastic Leukemia\nEstimated primary co
 mpletion: 30 September 2027. This is a ClinicalTrials.gov estimate\, not a
  confirmed readout date\, and it can move.\nDrug page: https://assetmemo.b
 io/drug/methotrexate#upcoming-events\nRegistry record: https://clinicaltri
 als.gov/study/NCT03914625
URL:https://assetmemo.bio/drug/methotrexate#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07477691-3826@assetmemo.bio
DTSTAMP:20261121T004007Z
DTSTART;VALUE=DATE:20270930
DTEND;VALUE=DATE:20271001
SUMMARY:Methotrexate: Phase 4 readout est. (NCT07477691)
DESCRIPTION:Methotrexate\, phase 4.\nStudy: Immune Modulation During Palynz
 iq® Treatment in Adults (IMPALA)\nEstimated primary completion: 30 Septem
 ber 2027. This is a ClinicalTrials.gov estimate\, not a confirmed readout 
 date\, and it can move.\nDrug page: https://assetmemo.bio/drug/methotrexat
 e#upcoming-events\nRegistry record: https://clinicaltrials.gov/study/NCT07
 477691
URL:https://assetmemo.bio/drug/methotrexate#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06973811-3826@assetmemo.bio
DTSTAMP:20261121T004007Z
DTSTART;VALUE=DATE:20271030
DTEND;VALUE=DATE:20271031
SUMMARY:Methotrexate: Phase 2 readout est. (NCT06973811)
DESCRIPTION:Methotrexate\, phase 2.\nStudy: ZR-MTX for PIOL Phase II Trial\
 nEstimated primary completion: 30 October 2027. This is a ClinicalTrials.g
 ov estimate\, not a confirmed readout date\, and it can move.\nDrug page: 
 https://assetmemo.bio/drug/methotrexate#upcoming-events\nRegistry record: 
 https://clinicaltrials.gov/study/NCT06973811
URL:https://assetmemo.bio/drug/methotrexate#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT01424982-3826@assetmemo.bio
DTSTAMP:20261121T004007Z
DTSTART;VALUE=DATE:20271031
DTEND;VALUE=DATE:20271101
SUMMARY:Methotrexate: Phase 2 readout est. (NCT01424982)
DESCRIPTION:Methotrexate\, phase 2\, Acute Lymphoblastic Leukemia.\nStudy: 
 Combination Chemotherapy and Ponatinib Hydrochloride in Treating Patients 
 With Acute Lymphoblastic Leukemia\nEstimated primary completion: 31 Octobe
 r 2027. This is a ClinicalTrials.gov estimate\, not a confirmed readout da
 te\, and it can move.\nDrug page: https://assetmemo.bio/drug/methotrexate#
 upcoming-events\nRegistry record: https://clinicaltrials.gov/study/NCT0142
 4982
URL:https://assetmemo.bio/drug/methotrexate#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT03684980-3826@assetmemo.bio
DTSTAMP:20261121T004007Z
DTSTART;VALUE=DATE:20271130
DTEND;VALUE=DATE:20271201
SUMMARY:Methotrexate: Phase 1 readout est. (NCT03684980)
DESCRIPTION:Methotrexate\, phase 1.\nStudy: LTA Pilot Study of Glucarpidase
  in Patients With Central Nervous System Lymphoma\nEstimated primary compl
 etion: November 2027. This is a ClinicalTrials.gov estimate\, not a confir
 med readout date\, and it can move.\nDrug page: https://assetmemo.bio/drug
 /methotrexate#upcoming-events\nRegistry record: https://clinicaltrials.gov
 /study/NCT03684980
URL:https://assetmemo.bio/drug/methotrexate#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT03150693-3826@assetmemo.bio
DTSTAMP:20261121T004007Z
DTSTART;VALUE=DATE:20271101
DTEND;VALUE=DATE:20271102
SUMMARY:Methotrexate: Phase 3 readout est. (NCT03150693)
DESCRIPTION:Methotrexate\, phase 3\, Acute Lymphoblastic Leukemia.\nStudy: 
 Inotuzumab Ozogamicin and Frontline Chemotherapy in Treating Young Adults 
 With Newly Diagnosed B Acute Lymphoblastic Leukemia\nEstimated primary com
 pletion: 1 November 2027. This is a ClinicalTrials.gov estimate\, not a co
 nfirmed readout date\, and it can move.\nDrug page: https://assetmemo.bio/
 drug/methotrexate#upcoming-events\nRegistry record: https://clinicaltrials
 .gov/study/NCT03150693
URL:https://assetmemo.bio/drug/methotrexate#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07381556-3826@assetmemo.bio
DTSTAMP:20261121T004007Z
DTSTART;VALUE=DATE:20271101
DTEND;VALUE=DATE:20271102
SUMMARY:Methotrexate: Phase 4 readout est. (NCT07381556)
DESCRIPTION:Methotrexate\, phase 4.\nStudy: Cyclosporine Or Methotrexate fo
 r Pediatric Alopecia Areata: Routine Clinical Care Effectiveness Study\nEs
 timated primary completion: 1 November 2027. This is a ClinicalTrials.gov 
 estimate\, not a confirmed readout date\, and it can move.\nDrug page: htt
 ps://assetmemo.bio/drug/methotrexate#upcoming-events\nRegistry record: htt
 ps://clinicaltrials.gov/study/NCT07381556
URL:https://assetmemo.bio/drug/methotrexate#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT03263572-3826@assetmemo.bio
DTSTAMP:20261121T004007Z
DTSTART;VALUE=DATE:20271130
DTEND;VALUE=DATE:20271201
SUMMARY:Methotrexate: Phase 2 readout est. (NCT03263572)
DESCRIPTION:Methotrexate\, phase 2\, Acute Lymphoblastic Leukemia.\nStudy: 
 Blinatumomab\, Methotrexate\, Cytarabine\, and Ponatinib in Treating Patie
 nts With Philadelphia Chromosome-Positive\, or BCR-ABL Positive\, or Relap
 sed/Refractory\, Acute Lymphoblastic Leukemia\nEstimated primary completio
 n: 30 November 2027. This is a ClinicalTrials.gov estimate\, not a confirm
 ed readout date\, and it can move.\nDrug page: https://assetmemo.bio/drug/
 methotrexate#upcoming-events\nRegistry record: https://clinicaltrials.gov/
 study/NCT03263572
URL:https://assetmemo.bio/drug/methotrexate#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06390319-3826@assetmemo.bio
DTSTAMP:20261121T004007Z
DTSTART;VALUE=DATE:20271231
DTEND;VALUE=DATE:20280101
SUMMARY:Methotrexate: Phase 2 readout est. (NCT06390319)
DESCRIPTION:Methotrexate\, phase 2\, Acute Lymphoblastic Leukemia.\nStudy: 
 Adding Dasatinib Or Venetoclax To Improve Responses In Children With Newly
  Diagnosed T-Cell Acute Lymphoblastic Leukemia (ALL) Or Lymphoma (T-LLY) O
 r Mixed Phenotype Acute Leukemia (MPAL)\nEstimated primary completion: Dec
 ember 2027. This is a ClinicalTrials.gov estimate\, not a confirmed readou
 t date\, and it can move.\nDrug page: https://assetmemo.bio/drug/methotrex
 ate#upcoming-events\nRegistry record: https://clinicaltrials.gov/study/NCT
 06390319
URL:https://assetmemo.bio/drug/methotrexate#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07280156-3826@assetmemo.bio
DTSTAMP:20261121T004007Z
DTSTART;VALUE=DATE:20271231
DTEND;VALUE=DATE:20280101
SUMMARY:Methotrexate: Phase 2 readout est. (NCT07280156)
DESCRIPTION:Methotrexate\, phase 2.\nStudy: A Study to Investigate the Clin
 ical Effect and the Safety of PRX-115 Infused Intravenously at Different D
 osing Regimens\, With and Without Methotrexate\, Versus Placebo in Adults 
 Gout Patients (RELEASE)\nEstimated primary completion: December 2027. This
  is a ClinicalTrials.gov estimate\, not a confirmed readout date\, and it 
 can move.\nDrug page: https://assetmemo.bio/drug/methotrexate#upcoming-eve
 nts\nRegistry record: https://clinicaltrials.gov/study/NCT07280156
URL:https://assetmemo.bio/drug/methotrexate#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06653634-3826@assetmemo.bio
DTSTAMP:20261121T004007Z
DTSTART;VALUE=DATE:20271231
DTEND;VALUE=DATE:20280101
SUMMARY:Methotrexate: Phase 4 readout est. (NCT06653634)
DESCRIPTION:Methotrexate\, phase 4.\nStudy: Optimizing Treatment for Patien
 ts With Juvenile Idiopathic Arthritis in Sustained Remission: The MOVE-JIA
  Trial\nEstimated primary completion: December 2027. This is a ClinicalTri
 als.gov estimate\, not a confirmed readout date\, and it can move.\nDrug p
 age: https://assetmemo.bio/drug/methotrexate#upcoming-events\nRegistry rec
 ord: https://clinicaltrials.gov/study/NCT06653634
URL:https://assetmemo.bio/drug/methotrexate#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07926698-3826@assetmemo.bio
DTSTAMP:20261121T004007Z
DTSTART;VALUE=DATE:20271201
DTEND;VALUE=DATE:20271202
SUMMARY:Methotrexate: Phase 2 readout est. (NCT07926698)
DESCRIPTION:Methotrexate\, phase 2.\nStudy: Lanoracopan to Prevent Acute GV
 HD Following Haploidentical Peripheral Blood Stem Cell Transplantation: A 
 Prospective Multicenter Single-Arm Exploratory Study\nEstimated primary co
 mpletion: 1 December 2027. This is a ClinicalTrials.gov estimate\, not a c
 onfirmed readout date\, and it can move.\nDrug page: https://assetmemo.bio
 /drug/methotrexate#upcoming-events\nRegistry record: https://clinicaltrial
 s.gov/study/NCT07926698
URL:https://assetmemo.bio/drug/methotrexate#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06946407-3826@assetmemo.bio
DTSTAMP:20261121T004007Z
DTSTART;VALUE=DATE:20271201
DTEND;VALUE=DATE:20271202
SUMMARY:Methotrexate: Phase na readout est. (NCT06946407)
DESCRIPTION:Methotrexate\, phase na.\nStudy: Rituximab\, Methotrexate\, and
  Tepadina Induction Followed by Etoposide and Cytarabine Consolidation in 
 Primary Central Nervous System Lymphoma\nEstimated primary completion: 1 D
 ecember 2027. This is a ClinicalTrials.gov estimate\, not a confirmed read
 out date\, and it can move.\nDrug page: https://assetmemo.bio/drug/methotr
 exate#upcoming-events\nRegistry record: https://clinicaltrials.gov/study/N
 CT06946407
URL:https://assetmemo.bio/drug/methotrexate#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT04872790-3826@assetmemo.bio
DTSTAMP:20261121T004007Z
DTSTART;VALUE=DATE:20271202
DTEND;VALUE=DATE:20271203
SUMMARY:Methotrexate: Phase 1 readout est. (NCT04872790)
DESCRIPTION:Methotrexate\, phase 1\, Acute Lymphoblastic Leukemia.\nStudy: 
 Venetoclax\, Dasatinib\, Prednisone\, Rituximab and Blinatumomab for the T
 reatment of Newly Diagnosed or Relapsed Philadelphia Chromosome Positive A
 cute Lymphoblastic Leukemia or Mixed Phenotype Acute Leukemia\nEstimated p
 rimary completion: 2 December 2027. This is a ClinicalTrials.gov estimate\
 , not a confirmed readout date\, and it can move.\nDrug page: https://asse
 tmemo.bio/drug/methotrexate#upcoming-events\nRegistry record: https://clin
 icaltrials.gov/study/NCT04872790
URL:https://assetmemo.bio/drug/methotrexate#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT05660473-3826@assetmemo.bio
DTSTAMP:20261121T004007Z
DTSTART;VALUE=DATE:20271215
DTEND;VALUE=DATE:20271216
SUMMARY:Methotrexate: Phase 2 readout est. (NCT05660473)
DESCRIPTION:Methotrexate\, phase 2\, Acute Lymphoblastic Leukemia.\nStudy: 
 Pediatric-inspired Regimen Combined With Venetoclax for Adolescent and Adu
 lt Patients With de Novo Philadelphia Chromosome-Negative Acute Lymphoblas
 tic Leukemia\nEstimated primary completion: 15 December 2027. This is a Cl
 inicalTrials.gov estimate\, not a confirmed readout date\, and it can move
 .\nDrug page: https://assetmemo.bio/drug/methotrexate#upcoming-events\nReg
 istry record: https://clinicaltrials.gov/study/NCT05660473
URL:https://assetmemo.bio/drug/methotrexate#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT01371630-3826@assetmemo.bio
DTSTAMP:20261121T004007Z
DTSTART;VALUE=DATE:20271225
DTEND;VALUE=DATE:20271226
SUMMARY:Methotrexate: Phase 1/2 readout est. (NCT01371630)
DESCRIPTION:Methotrexate\, phase 1/2\, Acute Lymphoblastic Leukemia.\nStudy
 : Inotuzumab Ozogamicin and Combination Chemotherapy in Treating Patients 
 With Acute Lymphoblastic Leukemia\nEstimated primary completion: 25 Decemb
 er 2027. This is a ClinicalTrials.gov estimate\, not a confirmed readout d
 ate\, and it can move.\nDrug page: https://assetmemo.bio/drug/methotrexate
 #upcoming-events\nRegistry record: https://clinicaltrials.gov/study/NCT013
 71630
URL:https://assetmemo.bio/drug/methotrexate#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07242092-3826@assetmemo.bio
DTSTAMP:20261121T004007Z
DTSTART;VALUE=DATE:20271230
DTEND;VALUE=DATE:20271231
SUMMARY:Methotrexate: Phase 4 readout est. (NCT07242092)
DESCRIPTION:Methotrexate\, phase 4.\nStudy: Influence of Methotrexate Disco
 ntinuation on Immunogenicity After PCV-20 Vaccine in Patients ARDs\nEstima
 ted primary completion: 30 December 2027. This is a ClinicalTrials.gov est
 imate\, not a confirmed readout date\, and it can move.\nDrug page: https:
 //assetmemo.bio/drug/methotrexate#upcoming-events\nRegistry record: https:
 //clinicaltrials.gov/study/NCT07242092
URL:https://assetmemo.bio/drug/methotrexate#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT03719105-3826@assetmemo.bio
DTSTAMP:20261121T004007Z
DTSTART;VALUE=DATE:20271231
DTEND;VALUE=DATE:20280101
SUMMARY:Methotrexate: Phase 1 readout est. (NCT03719105)
DESCRIPTION:Methotrexate\, phase 1.\nStudy: Chemoimmunotherapy and Allogene
 ic Stem Cell Transplant for NK T-cell Leukemia/Lymphoma\nEstimated primary
  completion: 31 December 2027. This is a ClinicalTrials.gov estimate\, not
  a confirmed readout date\, and it can move.\nDrug page: https://assetmemo
 .bio/drug/methotrexate#upcoming-events\nRegistry record: https://clinicalt
 rials.gov/study/NCT03719105
URL:https://assetmemo.bio/drug/methotrexate#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT05761171-3826@assetmemo.bio
DTSTAMP:20261121T004007Z
DTSTART;VALUE=DATE:20271231
DTEND;VALUE=DATE:20280101
SUMMARY:Methotrexate: Phase 2 readout est. (NCT05761171)
DESCRIPTION:Methotrexate\, phase 2\, Acute Lymphoblastic Leukemia.\nStudy: 
 A Study of Revumenib in Combination With Chemotherapy for Patients Diagnos
 ed With Relapsed or Refractory Leukemia\nEstimated primary completion: 31 
 December 2027. This is a ClinicalTrials.gov estimate\, not a confirmed rea
 dout date\, and it can move.\nDrug page: https://assetmemo.bio/drug/methot
 rexate#upcoming-events\nRegistry record: https://clinicaltrials.gov/study/
 NCT05761171
URL:https://assetmemo.bio/drug/methotrexate#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT05645718-3826@assetmemo.bio
DTSTAMP:20261121T004007Z
DTSTART;VALUE=DATE:20271231
DTEND;VALUE=DATE:20280101
SUMMARY:Methotrexate: Phase 2 readout est. (NCT05645718)
DESCRIPTION:Methotrexate\, phase 2.\nStudy: Study of Pedi-cRIB: Mini-Hyper-
 CVD With Condensed Rituximab\, Inotuzumab Ozogamicin and Blinatumomab (cRI
 B) for Relapsed Therapy for Pediatric With B-Cell Lineage Acute Lymphocyti
 c Leukemia\nEstimated primary completion: 31 December 2027. This is a Clin
 icalTrials.gov estimate\, not a confirmed readout date\, and it can move.\
 nDrug page: https://assetmemo.bio/drug/methotrexate#upcoming-events\nRegis
 try record: https://clinicaltrials.gov/study/NCT05645718
URL:https://assetmemo.bio/drug/methotrexate#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06913907-3826@assetmemo.bio
DTSTAMP:20261121T004007Z
DTSTART;VALUE=DATE:20271231
DTEND;VALUE=DATE:20280101
SUMMARY:Methotrexate: Phase 4 readout est. (NCT06913907)
DESCRIPTION:Methotrexate\, phase 4\, Rheumatoid Arthritis.\nStudy: Changes 
 in MTX-PG Concentrations During Subcutaneous MTX Therapy in Patients With 
 Rheumatoid Arthritis(COSMOS Study)\nEstimated primary completion: 31 Decem
 ber 2027. This is a ClinicalTrials.gov estimate\, not a confirmed readout 
 date\, and it can move.\nDrug page: https://assetmemo.bio/drug/methotrexat
 e#upcoming-events\nRegistry record: https://clinicaltrials.gov/study/NCT06
 913907
URL:https://assetmemo.bio/drug/methotrexate#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07486843-3826@assetmemo.bio
DTSTAMP:20261121T004007Z
DTSTART;VALUE=DATE:20271231
DTEND;VALUE=DATE:20280101
SUMMARY:Methotrexate: Phase 4 readout est. (NCT07486843)
DESCRIPTION:Methotrexate\, phase 4.\nStudy: Preventing Structural Damage in
  Early Psoriatic Arthritis\nEstimated primary completion: 31 December 2027
 . This is a ClinicalTrials.gov estimate\, not a confirmed readout date\, a
 nd it can move.\nDrug page: https://assetmemo.bio/drug/methotrexate#upcomi
 ng-events\nRegistry record: https://clinicaltrials.gov/study/NCT07486843
URL:https://assetmemo.bio/drug/methotrexate#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07138898-3826@assetmemo.bio
DTSTAMP:20261121T004007Z
DTSTART;VALUE=DATE:20280131
DTEND;VALUE=DATE:20280201
SUMMARY:Methotrexate: Phase 2 readout est. (NCT07138898)
DESCRIPTION:Methotrexate\, phase 2.\nStudy: Immunosuppressant Management in
  Rheumatology Patients Undergoing Elective Total Shoulder Arthroplasty\nEs
 timated primary completion: January 2028. This is a ClinicalTrials.gov est
 imate\, not a confirmed readout date\, and it can move.\nDrug page: https:
 //assetmemo.bio/drug/methotrexate#upcoming-events\nRegistry record: https:
 //clinicaltrials.gov/study/NCT07138898
URL:https://assetmemo.bio/drug/methotrexate#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06646211-3826@assetmemo.bio
DTSTAMP:20261121T004007Z
DTSTART;VALUE=DATE:20280101
DTEND;VALUE=DATE:20280102
SUMMARY:Methotrexate: Phase 2 readout est. (NCT06646211)
DESCRIPTION:Methotrexate\, phase 2.\nStudy: High-dose Methotrexate Combined
  with Thiotepa and Zanubrutinib in the Treatment of Newly Diagnosed PCNSL 
 (MTZ)\nEstimated primary completion: 1 January 2028. This is a ClinicalTri
 als.gov estimate\, not a confirmed readout date\, and it can move.\nDrug p
 age: https://assetmemo.bio/drug/methotrexate#upcoming-events\nRegistry rec
 ord: https://clinicaltrials.gov/study/NCT06646211
URL:https://assetmemo.bio/drug/methotrexate#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06719479-3826@assetmemo.bio
DTSTAMP:20261121T004007Z
DTSTART;VALUE=DATE:20280101
DTEND;VALUE=DATE:20280102
SUMMARY:Methotrexate: Phase 2/3 readout est. (NCT06719479)
DESCRIPTION:Methotrexate\, phase 2/3.\nStudy: A Clinical Trial to Evaluate 
 Effect of IAE0972 Combined with Chemotherapy for R/M HNSCC or NPC(Note: It
  is Currently Phase II.).\nEstimated primary completion: 1 January 2028. T
 his is a ClinicalTrials.gov estimate\, not a confirmed readout date\, and 
 it can move.\nDrug page: https://assetmemo.bio/drug/methotrexate#upcoming-
 events\nRegistry record: https://clinicaltrials.gov/study/NCT06719479
URL:https://assetmemo.bio/drug/methotrexate#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07015242-3826@assetmemo.bio
DTSTAMP:20261121T004007Z
DTSTART;VALUE=DATE:20280109
DTEND;VALUE=DATE:20280110
SUMMARY:Methotrexate: Phase 2 readout est. (NCT07015242)
DESCRIPTION:Methotrexate\, phase 2.\nStudy: A Study of the Efficacy and Saf
 ety of Lisocabtagene Maraleucel (Liso-cel) as First-Line Therapy in Adults
  With Transplant-Ineligible Primary Central Nervous System Lymphoma\nEstim
 ated primary completion: 9 January 2028. This is a ClinicalTrials.gov esti
 mate\, not a confirmed readout date\, and it can move.\nDrug page: https:/
 /assetmemo.bio/drug/methotrexate#upcoming-events\nRegistry record: https:/
 /clinicaltrials.gov/study/NCT07015242
URL:https://assetmemo.bio/drug/methotrexate#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07501507-3826@assetmemo.bio
DTSTAMP:20261121T004007Z
DTSTART;VALUE=DATE:20280229
DTEND;VALUE=DATE:20280301
SUMMARY:Methotrexate: Phase 2/3 readout est. (NCT07501507)
DESCRIPTION:Methotrexate\, phase 2/3.\nStudy: Methotrexate Treatment in Han
 d Osteoarthritis Refractory to Usual Treatments\nEstimated primary complet
 ion: February 2028. This is a ClinicalTrials.gov estimate\, not a confirme
 d readout date\, and it can move.\nDrug page: https://assetmemo.bio/drug/m
 ethotrexate#upcoming-events\nRegistry record: https://clinicaltrials.gov/s
 tudy/NCT07501507
URL:https://assetmemo.bio/drug/methotrexate#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06943482-3826@assetmemo.bio
DTSTAMP:20261121T004007Z
DTSTART;VALUE=DATE:20280201
DTEND;VALUE=DATE:20280202
SUMMARY:Methotrexate: Phase 4 readout est. (NCT06943482)
DESCRIPTION:Methotrexate\, phase 4.\nStudy: Comparing Effectiveness of Ster
 oids and Methotrexate in Treatment of Chronic Inflammatory Breast Disease\
 nEstimated primary completion: 1 February 2028. This is a ClinicalTrials.g
 ov estimate\, not a confirmed readout date\, and it can move.\nDrug page: 
 https://assetmemo.bio/drug/methotrexate#upcoming-events\nRegistry record: 
 https://clinicaltrials.gov/study/NCT06943482
URL:https://assetmemo.bio/drug/methotrexate#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07477457-3826@assetmemo.bio
DTSTAMP:20261121T004007Z
DTSTART;VALUE=DATE:20280331
DTEND;VALUE=DATE:20280401
SUMMARY:Methotrexate: Phase 2 readout est. (NCT07477457)
DESCRIPTION:Methotrexate\, phase 2.\nStudy: A Study of Gefitinib\, Trametin
 ib\, Disulfiram\, and Sunitinib in Addition to Standard Chemotherapy in Pe
 ople With Osteosarcoma\nEstimated primary completion: March 2028. This is 
 a ClinicalTrials.gov estimate\, not a confirmed readout date\, and it can 
 move.\nDrug page: https://assetmemo.bio/drug/methotrexate#upcoming-events\
 nRegistry record: https://clinicaltrials.gov/study/NCT07477457
URL:https://assetmemo.bio/drug/methotrexate#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT03414502-3826@assetmemo.bio
DTSTAMP:20261121T004007Z
DTSTART;VALUE=DATE:20280331
DTEND;VALUE=DATE:20280401
SUMMARY:Methotrexate: Phase 3 readout est. (NCT03414502)
DESCRIPTION:Methotrexate\, phase 3\, Rheumatoid Arthritis.\nStudy: Treatmen
 t of Rheumatoid Arthritis With DMARDs: Predictors of Response\nEstimated p
 rimary completion: March 2028. This is a ClinicalTrials.gov estimate\, not
  a confirmed readout date\, and it can move.\nDrug page: https://assetmemo
 .bio/drug/methotrexate#upcoming-events\nRegistry record: https://clinicalt
 rials.gov/study/NCT03414502
URL:https://assetmemo.bio/drug/methotrexate#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT04747912-3826@assetmemo.bio
DTSTAMP:20261121T004007Z
DTSTART;VALUE=DATE:20280301
DTEND;VALUE=DATE:20280302
SUMMARY:Methotrexate: Phase 2 readout est. (NCT04747912)
DESCRIPTION:Methotrexate\, phase 2\, Acute Lymphoblastic Leukemia.\nStudy: 
 Study of Chemotherapy-Free Induction Regimen for Ph+ Acute Lymphoblastic L
 eukemia With Inotuzumab Ozogamicin (InO)\nEstimated primary completion: 1 
 March 2028. This is a ClinicalTrials.gov estimate\, not a confirmed readou
 t date\, and it can move.\nDrug page: https://assetmemo.bio/drug/methotrex
 ate#upcoming-events\nRegistry record: https://clinicaltrials.gov/study/NCT
 04747912
URL:https://assetmemo.bio/drug/methotrexate#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06247787-3826@assetmemo.bio
DTSTAMP:20261121T004007Z
DTSTART;VALUE=DATE:20280331
DTEND;VALUE=DATE:20280401
SUMMARY:Methotrexate: Phase 1 readout est. (NCT06247787)
DESCRIPTION:Methotrexate\, phase 1.\nStudy: A Study to Find the Highest Dos
 e of Imetelstat in Combination With Fludarabine and Cytarabine for Patient
 s With AML\, MDS or JMML That Has Come Back or Does Not Respond to Therapy
 \nEstimated primary completion: 31 March 2028. This is a ClinicalTrials.go
 v estimate\, not a confirmed readout date\, and it can move.\nDrug page: h
 ttps://assetmemo.bio/drug/methotrexate#upcoming-events\nRegistry record: h
 ttps://clinicaltrials.gov/study/NCT06247787
URL:https://assetmemo.bio/drug/methotrexate#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT03286634-3826@assetmemo.bio
DTSTAMP:20261121T004007Z
DTSTART;VALUE=DATE:20280331
DTEND;VALUE=DATE:20280401
SUMMARY:Methotrexate: Phase 2 readout est. (NCT03286634)
DESCRIPTION:Methotrexate\, phase 2\, Acute Lymphoblastic Leukemia.\nStudy: 
 ASIA Down Syndrome Acute Lymphoblastic Leukemia 2016\nEstimated primary co
 mpletion: 31 March 2028. This is a ClinicalTrials.gov estimate\, not a con
 firmed readout date\, and it can move.\nDrug page: https://assetmemo.bio/d
 rug/methotrexate#upcoming-events\nRegistry record: https://clinicaltrials.
 gov/study/NCT03286634
URL:https://assetmemo.bio/drug/methotrexate#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06541665-3826@assetmemo.bio
DTSTAMP:20261121T004007Z
DTSTART;VALUE=DATE:20280428
DTEND;VALUE=DATE:20280429
SUMMARY:Methotrexate: Phase 1 readout est. (NCT06541665)
DESCRIPTION:Methotrexate\, phase 1.\nStudy: Phase I Study Evaluating Tolera
 bility\, Safety\, Pharmacokinetics\, and Efficacy of Combined ONO-4059 and
  R-MPV Therapy for PCNSL\nEstimated primary completion: 28 April 2028. Thi
 s is a ClinicalTrials.gov estimate\, not a confirmed readout date\, and it
  can move.\nDrug page: https://assetmemo.bio/drug/methotrexate#upcoming-ev
 ents\nRegistry record: https://clinicaltrials.gov/study/NCT06541665
URL:https://assetmemo.bio/drug/methotrexate#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06533748-3826@assetmemo.bio
DTSTAMP:20261121T004007Z
DTSTART;VALUE=DATE:20280531
DTEND;VALUE=DATE:20280601
SUMMARY:Methotrexate: Phase 2 readout est. (NCT06533748)
DESCRIPTION:Methotrexate\, phase 2\, Acute Lymphoblastic Leukemia.\nStudy: 
 Therapy for Newly Diagnosed Patients With B-Cell Precursor Acute Lymphobla
 stic Leukemia and Lymphoma\nEstimated primary completion: May 2028. This i
 s a ClinicalTrials.gov estimate\, not a confirmed readout date\, and it ca
 n move.\nDrug page: https://assetmemo.bio/drug/methotrexate#upcoming-event
 s\nRegistry record: https://clinicaltrials.gov/study/NCT06533748
URL:https://assetmemo.bio/drug/methotrexate#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07643103-3826@assetmemo.bio
DTSTAMP:20261121T004007Z
DTSTART;VALUE=DATE:20280531
DTEND;VALUE=DATE:20280601
SUMMARY:Methotrexate: Phase 2 readout est. (NCT07643103)
DESCRIPTION:Methotrexate\, phase 2\, Acute Lymphoblastic Leukemia.\nStudy: 
 Immuno-Targeted Therapy Plus Low-Dose Chemotherapy for Newly Diagnosed Adu
 lt Ph-Negative B-ALL: A Prospective Umbrella Trial\nEstimated primary comp
 letion: 31 May 2028. This is a ClinicalTrials.gov estimate\, not a confirm
 ed readout date\, and it can move.\nDrug page: https://assetmemo.bio/drug/
 methotrexate#upcoming-events\nRegistry record: https://clinicaltrials.gov/
 study/NCT07643103
URL:https://assetmemo.bio/drug/methotrexate#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT05998642-3826@assetmemo.bio
DTSTAMP:20261121T004007Z
DTSTART;VALUE=DATE:20280531
DTEND;VALUE=DATE:20280601
SUMMARY:Methotrexate: Phase 2 readout est. (NCT05998642)
DESCRIPTION:Methotrexate\, phase 2.\nStudy: Ibrutinib Combination Therapy i
 n Transplant Ineligible Individuals With Newly Diagnosed Primary CNS Lymph
 oma\nEstimated primary completion: 31 May 2028. This is a ClinicalTrials.g
 ov estimate\, not a confirmed readout date\, and it can move.\nDrug page: 
 https://assetmemo.bio/drug/methotrexate#upcoming-events\nRegistry record: 
 https://clinicaltrials.gov/study/NCT05998642
URL:https://assetmemo.bio/drug/methotrexate#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06262438-3826@assetmemo.bio
DTSTAMP:20261121T004007Z
DTSTART;VALUE=DATE:20280630
DTEND;VALUE=DATE:20280701
SUMMARY:Methotrexate: Phase 2 readout est. (NCT06262438)
DESCRIPTION:Methotrexate\, phase 2.\nStudy: CHIP-AML22/Quizartinib: Quizart
 inib + Chemotherapy in Newly Diagnosed Pediatric FLT3-ITD+ and NPM1wt AML 
 Patients\nEstimated primary completion: June 2028. This is a ClinicalTrial
 s.gov estimate\, not a confirmed readout date\, and it can move.\nDrug pag
 e: https://assetmemo.bio/drug/methotrexate#upcoming-events\nRegistry recor
 d: https://clinicaltrials.gov/study/NCT06262438
URL:https://assetmemo.bio/drug/methotrexate#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT04931368-3826@assetmemo.bio
DTSTAMP:20261121T004007Z
DTSTART;VALUE=DATE:20280630
DTEND;VALUE=DATE:20280701
SUMMARY:Methotrexate: Phase 3 readout est. (NCT04931368)
DESCRIPTION:Methotrexate\, phase 3.\nStudy: OptiMATe: De-escalated Inductio
 n Treatment in Primary CNS Lymphoma\nEstimated primary completion: June 20
 28. This is a ClinicalTrials.gov estimate\, not a confirmed readout date\,
  and it can move.\nDrug page: https://assetmemo.bio/drug/methotrexate#upco
 ming-events\nRegistry record: https://clinicaltrials.gov/study/NCT04931368
URL:https://assetmemo.bio/drug/methotrexate#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT04546399-3826@assetmemo.bio
DTSTAMP:20261121T004007Z
DTSTART;VALUE=DATE:20280630
DTEND;VALUE=DATE:20280701
SUMMARY:Methotrexate: Phase 2 readout est. (NCT04546399)
DESCRIPTION:Methotrexate\, phase 2\, Acute Lymphoblastic Leukemia.\nStudy: 
 A Study to Compare Blinatumomab Alone to Blinatumomab With Nivolumab in Pa
 tients Diagnosed With First Relapse B-Cell Acute Lymphoblastic Leukemia (B
 -ALL)\nEstimated primary completion: 30 June 2028. This is a ClinicalTrial
 s.gov estimate\, not a confirmed readout date\, and it can move.\nDrug pag
 e: https://assetmemo.bio/drug/methotrexate#upcoming-events\nRegistry recor
 d: https://clinicaltrials.gov/study/NCT04546399
URL:https://assetmemo.bio/drug/methotrexate#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06204614-3826@assetmemo.bio
DTSTAMP:20261121T004007Z
DTSTART;VALUE=DATE:20280701
DTEND;VALUE=DATE:20280702
SUMMARY:Methotrexate: Phase 1 readout est. (NCT06204614)
DESCRIPTION:Methotrexate\, phase 1.\nStudy: Drug Screening Using IMD in Bla
 dder Cancer\nEstimated primary completion: 1 July 2028. This is a Clinical
 Trials.gov estimate\, not a confirmed readout date\, and it can move.\nDru
 g page: https://assetmemo.bio/drug/methotrexate#upcoming-events\nRegistry 
 record: https://clinicaltrials.gov/study/NCT06204614
URL:https://assetmemo.bio/drug/methotrexate#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT04530565-3826@assetmemo.bio
DTSTAMP:20261121T004007Z
DTSTART;VALUE=DATE:20280701
DTEND;VALUE=DATE:20280702
SUMMARY:Methotrexate: Phase 3 readout est. (NCT04530565)
DESCRIPTION:Methotrexate\, phase 3\, Acute Lymphoblastic Leukemia.\nStudy: 
 Testing the Use of Steroids and Tyrosine Kinase Inhibitors With Blinatumom
 ab or Chemotherapy for Newly Diagnosed BCR-ABL-Positive Acute Lymphoblasti
 c Leukemia in Adults\nEstimated primary completion: 1 July 2028. This is a
  ClinicalTrials.gov estimate\, not a confirmed readout date\, and it can m
 ove.\nDrug page: https://assetmemo.bio/drug/methotrexate#upcoming-events\n
 Registry record: https://clinicaltrials.gov/study/NCT04530565
URL:https://assetmemo.bio/drug/methotrexate#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT05292664-3826@assetmemo.bio
DTSTAMP:20261121T004007Z
DTSTART;VALUE=DATE:20280702
DTEND;VALUE=DATE:20280703
SUMMARY:Methotrexate: Phase 1 readout est. (NCT05292664)
DESCRIPTION:Methotrexate\, phase 1\, Acute Lymphoblastic Leukemia.\nStudy: 
 Venetoclax Basket Trial for High Risk Hematologic Malignancies\nEstimated 
 primary completion: 2 July 2028. This is a ClinicalTrials.gov estimate\, n
 ot a confirmed readout date\, and it can move.\nDrug page: https://assetme
 mo.bio/drug/methotrexate#upcoming-events\nRegistry record: https://clinica
 ltrials.gov/study/NCT05292664
URL:https://assetmemo.bio/drug/methotrexate#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT03643276-3826@assetmemo.bio
DTSTAMP:20261121T004007Z
DTSTART;VALUE=DATE:20280714
DTEND;VALUE=DATE:20280715
SUMMARY:Methotrexate: Phase 3 readout est. (NCT03643276)
DESCRIPTION:Methotrexate\, phase 3\, Acute Lymphoblastic Leukemia.\nStudy: 
 Treatment Protocol for Children and Adolescents With Acute Lymphoblastic L
 eukemia - AIEOP-BFM ALL 2017\nEstimated primary completion: 14 July 2028. 
 This is a ClinicalTrials.gov estimate\, not a confirmed readout date\, and
  it can move.\nDrug page: https://assetmemo.bio/drug/methotrexate#upcoming
 -events\nRegistry record: https://clinicaltrials.gov/study/NCT03643276
URL:https://assetmemo.bio/drug/methotrexate#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06265584-3826@assetmemo.bio
DTSTAMP:20261121T004007Z
DTSTART;VALUE=DATE:20280831
DTEND;VALUE=DATE:20280901
SUMMARY:Methotrexate: Phase 2 readout est. (NCT06265584)
DESCRIPTION:Methotrexate\, phase 2.\nStudy: Trial of 2 Step ATG for Prevent
 ion of Acute GVHD Post Allogeneic Stem Cell Transplant\nEstimated primary 
 completion: August 2028. This is a ClinicalTrials.gov estimate\, not a con
 firmed readout date\, and it can move.\nDrug page: https://assetmemo.bio/d
 rug/methotrexate#upcoming-events\nRegistry record: https://clinicaltrials.
 gov/study/NCT06265584
URL:https://assetmemo.bio/drug/methotrexate#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07764601-3826@assetmemo.bio
DTSTAMP:20261121T004007Z
DTSTART;VALUE=DATE:20280831
DTEND;VALUE=DATE:20280901
SUMMARY:Methotrexate: Phase na readout est. (NCT07764601)
DESCRIPTION:Methotrexate\, phase na.\nStudy: R-MA-PD-1 Versus R-MA in Treat
 ment-naive Primary CNS Lymphoma\nEstimated primary completion: August 2028
 . This is a ClinicalTrials.gov estimate\, not a confirmed readout date\, a
 nd it can move.\nDrug page: https://assetmemo.bio/drug/methotrexate#upcomi
 ng-events\nRegistry record: https://clinicaltrials.gov/study/NCT07764601
URL:https://assetmemo.bio/drug/methotrexate#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06960577-3826@assetmemo.bio
DTSTAMP:20261121T004007Z
DTSTART;VALUE=DATE:20280830
DTEND;VALUE=DATE:20280831
SUMMARY:Methotrexate: Phase 2 readout est. (NCT06960577)
DESCRIPTION:Methotrexate\, phase 2.\nStudy: Perioperative Durvalumab With N
 eoadjuvant ddMVAC in Patients With Muscle-Invasive Bladder Cancer (NIAGARA
 -2)\nEstimated primary completion: 30 August 2028. This is a ClinicalTrial
 s.gov estimate\, not a confirmed readout date\, and it can move.\nDrug pag
 e: https://assetmemo.bio/drug/methotrexate#upcoming-events\nRegistry recor
 d: https://clinicaltrials.gov/study/NCT06960577
URL:https://assetmemo.bio/drug/methotrexate#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT05137262-3826@assetmemo.bio
DTSTAMP:20261121T004007Z
DTSTART;VALUE=DATE:20280831
DTEND;VALUE=DATE:20280901
SUMMARY:Methotrexate: Phase 2 readout est. (NCT05137262)
DESCRIPTION:Methotrexate\, phase 2.\nStudy: A Phase II Multicenter Study of
  Chemotherapy Versus Chemotherapy Plus Durvalumab (MEDI 4736) in Patients 
 With Lymph Node Positive Urothelial Carcinoma of the Bladder\nEstimated pr
 imary completion: 31 August 2028. This is a ClinicalTrials.gov estimate\, 
 not a confirmed readout date\, and it can move.\nDrug page: https://assetm
 emo.bio/drug/methotrexate#upcoming-events\nRegistry record: https://clinic
 altrials.gov/study/NCT05137262
URL:https://assetmemo.bio/drug/methotrexate#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07812493-3826@assetmemo.bio
DTSTAMP:20261121T004007Z
DTSTART;VALUE=DATE:20280901
DTEND;VALUE=DATE:20280902
SUMMARY:Methotrexate: Phase 2 readout est. (NCT07812493)
DESCRIPTION:Methotrexate\, phase 2.\nStudy: Pirtobrutinib Plus Methotrexate
 -Based Chemoimmunotherapy for Systemic DLBCL With CNS Involvement\nEstimat
 ed primary completion: 1 September 2028. This is a ClinicalTrials.gov esti
 mate\, not a confirmed readout date\, and it can move.\nDrug page: https:/
 /assetmemo.bio/drug/methotrexate#upcoming-events\nRegistry record: https:/
 /clinicaltrials.gov/study/NCT07812493
URL:https://assetmemo.bio/drug/methotrexate#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07185373-3826@assetmemo.bio
DTSTAMP:20261121T004007Z
DTSTART;VALUE=DATE:20280930
DTEND;VALUE=DATE:20281001
SUMMARY:Methotrexate: Phase 2/3 readout est. (NCT07185373)
DESCRIPTION:Methotrexate\, phase 2/3.\nStudy: Orelabrutinib Combined With T
 eniposide\, Rituximab and Methotrexate for Newly Diagnosed PCNSL\nEstimate
 d primary completion: 30 September 2028. This is a ClinicalTrials.gov esti
 mate\, not a confirmed readout date\, and it can move.\nDrug page: https:/
 /assetmemo.bio/drug/methotrexate#upcoming-events\nRegistry record: https:/
 /clinicaltrials.gov/study/NCT07185373
URL:https://assetmemo.bio/drug/methotrexate#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07914166-3826@assetmemo.bio
DTSTAMP:20261121T004007Z
DTSTART;VALUE=DATE:20281013
DTEND;VALUE=DATE:20281014
SUMMARY:Methotrexate: Phase 1 readout est. (NCT07914166)
DESCRIPTION:Methotrexate\, phase 1\, Acute Lymphoblastic Leukemia.\nStudy: 
 Asciminib-Based Induction Therapy for the Treatment of Newly Diagnosed Phi
 ladelphia Chromosome-Positive Acute Lymphoblastic Leukemia\nEstimated prim
 ary completion: 13 October 2028. This is a ClinicalTrials.gov estimate\, n
 ot a confirmed readout date\, and it can move.\nDrug page: https://assetme
 mo.bio/drug/methotrexate#upcoming-events\nRegistry record: https://clinica
 ltrials.gov/study/NCT07914166
URL:https://assetmemo.bio/drug/methotrexate#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT00501826-3826@assetmemo.bio
DTSTAMP:20261121T004007Z
DTSTART;VALUE=DATE:20281031
DTEND;VALUE=DATE:20281101
SUMMARY:Methotrexate: Phase 2 readout est. (NCT00501826)
DESCRIPTION:Methotrexate\, phase 2\, Acute Lymphoblastic Leukemia.\nStudy: 
 Combination Chemotherapy and Nelarabine in Treating Patients With T-cell A
 cute Lymphoblastic Leukemia or Lymphoblastic Lymphoma\nEstimated primary c
 ompletion: 31 October 2028. This is a ClinicalTrials.gov estimate\, not a 
 confirmed readout date\, and it can move.\nDrug page: https://assetmemo.bi
 o/drug/methotrexate#upcoming-events\nRegistry record: https://clinicaltria
 ls.gov/study/NCT00501826
URL:https://assetmemo.bio/drug/methotrexate#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT02877303-3826@assetmemo.bio
DTSTAMP:20261121T004007Z
DTSTART;VALUE=DATE:20281101
DTEND;VALUE=DATE:20281102
SUMMARY:Methotrexate: Phase 2 readout est. (NCT02877303)
DESCRIPTION:Methotrexate\, phase 2\, Acute Lymphoblastic Leukemia.\nStudy: 
 Blinatumomab\, Inotuzumab Ozogamicin\, and Combination Chemotherapy as Fro
 ntline Therapy in Treating Patients With B Acute Lymphoblastic Leukemia\nE
 stimated primary completion: 1 November 2028. This is a ClinicalTrials.gov
  estimate\, not a confirmed readout date\, and it can move.\nDrug page: ht
 tps://assetmemo.bio/drug/methotrexate#upcoming-events\nRegistry record: ht
 tps://clinicaltrials.gov/study/NCT02877303
URL:https://assetmemo.bio/drug/methotrexate#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT05848687-3826@assetmemo.bio
DTSTAMP:20261121T004007Z
DTSTART;VALUE=DATE:20281231
DTEND;VALUE=DATE:20290101
SUMMARY:Methotrexate: Phase 1/2 readout est. (NCT05848687)
DESCRIPTION:Methotrexate\, phase 1/2\, Acute Lymphoblastic Leukemia.\nStudy
 : TINI 2: Total Therapy for Infants With Acute Lymphoblastic Leukemia II\n
 Estimated primary completion: December 2028. This is a ClinicalTrials.gov 
 estimate\, not a confirmed readout date\, and it can move.\nDrug page: htt
 ps://assetmemo.bio/drug/methotrexate#upcoming-events\nRegistry record: htt
 ps://clinicaltrials.gov/study/NCT05848687
URL:https://assetmemo.bio/drug/methotrexate#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06541574-3826@assetmemo.bio
DTSTAMP:20261121T004007Z
DTSTART;VALUE=DATE:20281231
DTEND;VALUE=DATE:20290101
SUMMARY:Methotrexate: Phase 2 readout est. (NCT06541574)
DESCRIPTION:Methotrexate\, phase 2.\nStudy: Prevention of ProliFerative Vit
 reoretinopathy With Intravitreal MethotreXate in Primary Retinal DEtachmen
 t Repair (FIXER) Trial\nEstimated primary completion: December 2028. This 
 is a ClinicalTrials.gov estimate\, not a confirmed readout date\, and it c
 an move.\nDrug page: https://assetmemo.bio/drug/methotrexate#upcoming-even
 ts\nRegistry record: https://clinicaltrials.gov/study/NCT06541574
URL:https://assetmemo.bio/drug/methotrexate#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07560826-3826@assetmemo.bio
DTSTAMP:20261121T004007Z
DTSTART;VALUE=DATE:20281231
DTEND;VALUE=DATE:20290101
SUMMARY:Methotrexate: Phase 2 readout est. (NCT07560826)
DESCRIPTION:Methotrexate\, phase 2.\nStudy: The CATSINDO Trial - Clinical a
 nd Translational Study in Newly Diagnosed Osteosarcoma\nEstimated primary 
 completion: December 2028. This is a ClinicalTrials.gov estimate\, not a c
 onfirmed readout date\, and it can move.\nDrug page: https://assetmemo.bio
 /drug/methotrexate#upcoming-events\nRegistry record: https://clinicaltrial
 s.gov/study/NCT07560826
URL:https://assetmemo.bio/drug/methotrexate#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07002099-3826@assetmemo.bio
DTSTAMP:20261121T004007Z
DTSTART;VALUE=DATE:20281230
DTEND;VALUE=DATE:20281231
SUMMARY:Methotrexate: Phase 2 readout est. (NCT07002099)
DESCRIPTION:Methotrexate\, phase 2.\nStudy: Selinexor\, High-dose Methotrex
 ate\, and Rituximab Combined With Radiotherapy for Newly Diagnosed\, Trans
 plant-ineligible Patients With Central Nervous System Lymphoma: An Open-la
 bel\, Single-arm\, Multicenter Phase II Study\nEstimated primary completio
 n: 30 December 2028. This is a ClinicalTrials.gov estimate\, not a confirm
 ed readout date\, and it can move.\nDrug page: https://assetmemo.bio/drug/
 methotrexate#upcoming-events\nRegistry record: https://clinicaltrials.gov/
 study/NCT07002099
URL:https://assetmemo.bio/drug/methotrexate#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07410520-3826@assetmemo.bio
DTSTAMP:20261121T004007Z
DTSTART;VALUE=DATE:20281231
DTEND;VALUE=DATE:20290101
SUMMARY:Methotrexate: Phase 2 readout est. (NCT07410520)
DESCRIPTION:Methotrexate\, phase 2.\nStudy: PD-1 Inhibitor Combined With Ri
 tuximab\, Methotrexate\, and Orelabrutinib (PD-1i+RMO) for Newly Diagnosed
  PCNSL and SCNSL.\nEstimated primary completion: 31 December 2028. This is
  a ClinicalTrials.gov estimate\, not a confirmed readout date\, and it can
  move.\nDrug page: https://assetmemo.bio/drug/methotrexate#upcoming-events
 \nRegistry record: https://clinicaltrials.gov/study/NCT07410520
URL:https://assetmemo.bio/drug/methotrexate#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07350850-3826@assetmemo.bio
DTSTAMP:20261121T004007Z
DTSTART;VALUE=DATE:20281231
DTEND;VALUE=DATE:20290101
SUMMARY:Methotrexate: Phase 2 readout est. (NCT07350850)
DESCRIPTION:Methotrexate\, phase 2.\nStudy: A Multicenter\, Prospective Cli
 nical Trial With a Concurrent Control Evaluating Methotrexate Combined Wit
 h Rituximab\,Sintilimab and Pirtobrutinib vs. Investigator-Selected Standa
 rd of Care in Treatment-Naive PCNSL\nEstimated primary completion: 31 Dece
 mber 2028. This is a ClinicalTrials.gov estimate\, not a confirmed readout
  date\, and it can move.\nDrug page: https://assetmemo.bio/drug/methotrexa
 te#upcoming-events\nRegistry record: https://clinicaltrials.gov/study/NCT0
 7350850
URL:https://assetmemo.bio/drug/methotrexate#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT03970096-3826@assetmemo.bio
DTSTAMP:20261121T004007Z
DTSTART;VALUE=DATE:20281231
DTEND;VALUE=DATE:20290101
SUMMARY:Methotrexate: Phase 2 readout est. (NCT03970096)
DESCRIPTION:Methotrexate\, phase 2\, Acute Lymphoblastic Leukemia.\nStudy: 
 Graft Versus Host Disease-Reduction Strategies for Donor Blood Stem Cell T
 ransplant Patients With Acute Leukemia or Myelodysplastic Syndrome (MDS)\n
 Estimated primary completion: 31 December 2028. This is a ClinicalTrials.g
 ov estimate\, not a confirmed readout date\, and it can move.\nDrug page: 
 https://assetmemo.bio/drug/methotrexate#upcoming-events\nRegistry record: 
 https://clinicaltrials.gov/study/NCT03970096
URL:https://assetmemo.bio/drug/methotrexate#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT03964090-3826@assetmemo.bio
DTSTAMP:20261121T004007Z
DTSTART;VALUE=DATE:20281231
DTEND;VALUE=DATE:20290101
SUMMARY:Methotrexate: Phase 2 readout est. (NCT03964090)
DESCRIPTION:Methotrexate\, phase 2.\nStudy: Temozolomide\, Etoposide\, Doxi
 l\, Dexamethasone\, Ibrutinib\, and Rituximab (TEDDI-R) in Aggressive B-ce
 ll Lymphomas With Secondary Involvement of the Central Nervous System (CNS
 )\nEstimated primary completion: 31 December 2028. This is a ClinicalTrial
 s.gov estimate\, not a confirmed readout date\, and it can move.\nDrug pag
 e: https://assetmemo.bio/drug/methotrexate#upcoming-events\nRegistry recor
 d: https://clinicaltrials.gov/study/NCT03964090
URL:https://assetmemo.bio/drug/methotrexate#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07301138-3826@assetmemo.bio
DTSTAMP:20261121T004007Z
DTSTART;VALUE=DATE:20281231
DTEND;VALUE=DATE:20290101
SUMMARY:Methotrexate: Phase 2 readout est. (NCT07301138)
DESCRIPTION:Methotrexate\, phase 2\, Acute Lymphoblastic Leukemia.\nStudy: 
 BEBT-908 Plus Chemotherapy Treatment for CR MRD-Positive MEF2D-Rearranged 
 and Pre-B Acute Lymphoblastic Leukemia Patients\nEstimated primary complet
 ion: 31 December 2028. This is a ClinicalTrials.gov estimate\, not a confi
 rmed readout date\, and it can move.\nDrug page: https://assetmemo.bio/dru
 g/methotrexate#upcoming-events\nRegistry record: https://clinicaltrials.go
 v/study/NCT07301138
URL:https://assetmemo.bio/drug/methotrexate#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06317662-3826@assetmemo.bio
DTSTAMP:20261121T004007Z
DTSTART;VALUE=DATE:20281231
DTEND;VALUE=DATE:20290101
SUMMARY:Methotrexate: Phase 2 readout est. (NCT06317662)
DESCRIPTION:Methotrexate\, phase 2\, Acute Lymphoblastic Leukemia.\nStudy: 
 Testing the Addition of the Anti-cancer Drug Venetoclax and/or the Anti-ca
 ncer Immunotherapy Blinatumomab to the Usual Chemotherapy Treatment for In
 fants With Newly Diagnosed KMT2A-rearranged or KMT2A-non-rearranged Leukem
 ia\nEstimated primary completion: 31 December 2028. This is a ClinicalTria
 ls.gov estimate\, not a confirmed readout date\, and it can move.\nDrug pa
 ge: https://assetmemo.bio/drug/methotrexate#upcoming-events\nRegistry reco
 rd: https://clinicaltrials.gov/study/NCT06317662
URL:https://assetmemo.bio/drug/methotrexate#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT04960579-3826@assetmemo.bio
DTSTAMP:20261121T004007Z
DTSTART;VALUE=DATE:20290331
DTEND;VALUE=DATE:20290401
SUMMARY:Methotrexate: Phase 1 readout est. (NCT04960579)
DESCRIPTION:Methotrexate\, phase 1.\nStudy: P-BCMA-ALLO1 Allogeneic CAR-T C
 ells in the Treatment of Subjects With Multiple Myeloma\nEstimated primary
  completion: March 2029. This is a ClinicalTrials.gov estimate\, not a con
 firmed readout date\, and it can move.\nDrug page: https://assetmemo.bio/d
 rug/methotrexate#upcoming-events\nRegistry record: https://clinicaltrials.
 gov/study/NCT04960579
URL:https://assetmemo.bio/drug/methotrexate#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06918431-3826@assetmemo.bio
DTSTAMP:20261121T004007Z
DTSTART;VALUE=DATE:20290330
DTEND;VALUE=DATE:20290331
SUMMARY:Methotrexate: Phase 2 readout est. (NCT06918431)
DESCRIPTION:Methotrexate\, phase 2\, Acute Lymphoblastic Leukemia.\nStudy: 
 Asparaginase Erwinia Chrysanthemi With Chemotherapy for the Treatment of H
 igh-Risk Adults With Newly Diagnosed Acute Lymphoblastic Leukemia or Lymph
 oblastic Lymphoma\nEstimated primary completion: 30 March 2029. This is a 
 ClinicalTrials.gov estimate\, not a confirmed readout date\, and it can mo
 ve.\nDrug page: https://assetmemo.bio/drug/methotrexate#upcoming-events\nR
 egistry record: https://clinicaltrials.gov/study/NCT06918431
URL:https://assetmemo.bio/drug/methotrexate#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07802678-3826@assetmemo.bio
DTSTAMP:20261121T004007Z
DTSTART;VALUE=DATE:20290501
DTEND;VALUE=DATE:20290502
SUMMARY:Methotrexate: Phase 4 readout est. (NCT07802678)
DESCRIPTION:Methotrexate\, phase 4\, Rheumatoid Arthritis.\nStudy: Disconti
 nuation of Disease-modifying Anti-rheumatic Drugs (DMARDs) in Rheumatoid A
 rthritis Patients Also Using TNF Inhibitors\nEstimated primary completion:
  1 May 2029. This is a ClinicalTrials.gov estimate\, not a confirmed reado
 ut date\, and it can move.\nDrug page: https://assetmemo.bio/drug/methotre
 xate#upcoming-events\nRegistry record: https://clinicaltrials.gov/study/NC
 T07802678
URL:https://assetmemo.bio/drug/methotrexate#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07627893-3826@assetmemo.bio
DTSTAMP:20261121T004007Z
DTSTART;VALUE=DATE:20290531
DTEND;VALUE=DATE:20290601
SUMMARY:Methotrexate: Phase 2/3 readout est. (NCT07627893)
DESCRIPTION:Methotrexate\, phase 2/3\, Rheumatoid Arthritis.\nStudy: Comple
 mentary Herbal Approach to Rheumatoid Management Study (CHARMS)\nEstimated
  primary completion: 31 May 2029. This is a ClinicalTrials.gov estimate\, 
 not a confirmed readout date\, and it can move.\nDrug page: https://assetm
 emo.bio/drug/methotrexate#upcoming-events\nRegistry record: https://clinic
 altrials.gov/study/NCT07627893
URL:https://assetmemo.bio/drug/methotrexate#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT04293562-3826@assetmemo.bio
DTSTAMP:20261121T004007Z
DTSTART;VALUE=DATE:20290630
DTEND;VALUE=DATE:20290701
SUMMARY:Methotrexate: Phase 3 readout est. (NCT04293562)
DESCRIPTION:Methotrexate\, phase 3.\nStudy: A Study to Compare Standard Che
 motherapy to Therapy With CPX-351 and/or Gilteritinib for Patients With Ne
 wly Diagnosed AML With or Without FLT3 Mutations\nEstimated primary comple
 tion: 30 June 2029. This is a ClinicalTrials.gov estimate\, not a confirme
 d readout date\, and it can move.\nDrug page: https://assetmemo.bio/drug/m
 ethotrexate#upcoming-events\nRegistry record: https://clinicaltrials.gov/s
 tudy/NCT04293562
URL:https://assetmemo.bio/drug/methotrexate#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06997068-3826@assetmemo.bio
DTSTAMP:20261121T004007Z
DTSTART;VALUE=DATE:20290805
DTEND;VALUE=DATE:20290806
SUMMARY:Methotrexate: Phase 2 readout est. (NCT06997068)
DESCRIPTION:Methotrexate\, phase 2.\nStudy: Methotrexate\, Erlotinib\, and 
 Celecoxib for the Treatment of Recurrent/Metastatic Head and Neck Cancer i
 n a Rural Midwest United States Population\nEstimated primary completion: 
 5 August 2029. This is a ClinicalTrials.gov estimate\, not a confirmed rea
 dout date\, and it can move.\nDrug page: https://assetmemo.bio/drug/methot
 rexate#upcoming-events\nRegistry record: https://clinicaltrials.gov/study/
 NCT06997068
URL:https://assetmemo.bio/drug/methotrexate#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06252870-3826@assetmemo.bio
DTSTAMP:20261121T004007Z
DTSTART;VALUE=DATE:20291018
DTEND;VALUE=DATE:20291019
SUMMARY:Methotrexate: Phase 2 readout est. (NCT06252870)
DESCRIPTION:Methotrexate\, phase 2.\nStudy: Study Testing Two Conditioning 
 Regimen With a Single Prophylaxis of GVHD by Cyclophosphamide and Methotre
 xate Post-transplant in Patients Eligible for Matched-donor Allograft Tran
 splantation\nEstimated primary completion: 18 October 2029. This is a Clin
 icalTrials.gov estimate\, not a confirmed readout date\, and it can move.\
 nDrug page: https://assetmemo.bio/drug/methotrexate#upcoming-events\nRegis
 try record: https://clinicaltrials.gov/study/NCT06252870
URL:https://assetmemo.bio/drug/methotrexate#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07686107-3826@assetmemo.bio
DTSTAMP:20261121T004007Z
DTSTART;VALUE=DATE:20291231
DTEND;VALUE=DATE:20300101
SUMMARY:Methotrexate: Phase 2 readout est. (NCT07686107)
DESCRIPTION:Methotrexate\, phase 2.\nStudy: Trial of Revumenib Plus FLA Che
 motherapy for Children With Relapsed or Refractory NUP98-rearranged AML."\
 nEstimated primary completion: 31 December 2029. This is a ClinicalTrials.
 gov estimate\, not a confirmed readout date\, and it can move.\nDrug page:
  https://assetmemo.bio/drug/methotrexate#upcoming-events\nRegistry record:
  https://clinicaltrials.gov/study/NCT07686107
URL:https://assetmemo.bio/drug/methotrexate#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06336395-3826@assetmemo.bio
DTSTAMP:20261121T004007Z
DTSTART;VALUE=DATE:20300331
DTEND;VALUE=DATE:20300401
SUMMARY:Methotrexate: Phase 2 readout est. (NCT06336395)
DESCRIPTION:Methotrexate\, phase 2.\nStudy: Ma-Spore ALL 2020 Study\nEstima
 ted primary completion: March 2030. This is a ClinicalTrials.gov estimate\
 , not a confirmed readout date\, and it can move.\nDrug page: https://asse
 tmemo.bio/drug/methotrexate#upcoming-events\nRegistry record: https://clin
 icaltrials.gov/study/NCT06336395
URL:https://assetmemo.bio/drug/methotrexate#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT04043494-3826@assetmemo.bio
DTSTAMP:20261121T004007Z
DTSTART;VALUE=DATE:20300422
DTEND;VALUE=DATE:20300423
SUMMARY:Methotrexate: Phase 3 readout est. (NCT04043494)
DESCRIPTION:Methotrexate\, phase 3.\nStudy: International Cooperative Treat
 ment Protocol for Children and Adolescents With Lymphoblastic Lymphoma\nEs
 timated primary completion: 22 April 2030. This is a ClinicalTrials.gov es
 timate\, not a confirmed readout date\, and it can move.\nDrug page: https
 ://assetmemo.bio/drug/methotrexate#upcoming-events\nRegistry record: https
 ://clinicaltrials.gov/study/NCT04043494
URL:https://assetmemo.bio/drug/methotrexate#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06730542-3826@assetmemo.bio
DTSTAMP:20261121T004007Z
DTSTART;VALUE=DATE:20300430
DTEND;VALUE=DATE:20300501
SUMMARY:Methotrexate: Phase 1 readout est. (NCT06730542)
DESCRIPTION:Methotrexate\, phase 1.\nStudy: Zanubrutinib in Combination Wit
 h Pola-R-CHP and High-dose Methotrexate in Patients With Secondary CNS Lym
 phoma\nEstimated primary completion: 30 April 2030. This is a ClinicalTria
 ls.gov estimate\, not a confirmed readout date\, and it can move.\nDrug pa
 ge: https://assetmemo.bio/drug/methotrexate#upcoming-events\nRegistry reco
 rd: https://clinicaltrials.gov/study/NCT06730542
URL:https://assetmemo.bio/drug/methotrexate#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07352566-3826@assetmemo.bio
DTSTAMP:20261121T004007Z
DTSTART;VALUE=DATE:20300601
DTEND;VALUE=DATE:20300602
SUMMARY:Methotrexate: Phase 4 readout est. (NCT07352566)
DESCRIPTION:Methotrexate\, phase 4.\nStudy: Utilization of a Microdevice fo
 r Psoriasis and Atopic Dermatitis\nEstimated primary completion: 1 June 20
 30. This is a ClinicalTrials.gov estimate\, not a confirmed readout date\,
  and it can move.\nDrug page: https://assetmemo.bio/drug/methotrexate#upco
 ming-events\nRegistry record: https://clinicaltrials.gov/study/NCT07352566
URL:https://assetmemo.bio/drug/methotrexate#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07168980-3826@assetmemo.bio
DTSTAMP:20261121T004007Z
DTSTART;VALUE=DATE:20300630
DTEND;VALUE=DATE:20300701
SUMMARY:Methotrexate: Phase 2/3 readout est. (NCT07168980)
DESCRIPTION:Methotrexate\, phase 2/3.\nStudy: Chemotherapy With Rituximab f
 or Aggressive B-NHL in Children and Adolescents\nEstimated primary complet
 ion: 30 June 2030. This is a ClinicalTrials.gov estimate\, not a confirmed
  readout date\, and it can move.\nDrug page: https://assetmemo.bio/drug/me
 thotrexate#upcoming-events\nRegistry record: https://clinicaltrials.gov/st
 udy/NCT07168980
URL:https://assetmemo.bio/drug/methotrexate#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07227584-3826@assetmemo.bio
DTSTAMP:20261121T004007Z
DTSTART;VALUE=DATE:20300731
DTEND;VALUE=DATE:20300801
SUMMARY:Methotrexate: Phase 2 readout est. (NCT07227584)
DESCRIPTION:Methotrexate\, phase 2\, Acute Lymphoblastic Leukemia.\nStudy: 
 ALL Backbone in AYAs\nEstimated primary completion: 31 July 2030. This is 
 a ClinicalTrials.gov estimate\, not a confirmed readout date\, and it can 
 move.\nDrug page: https://assetmemo.bio/drug/methotrexate#upcoming-events\
 nRegistry record: https://clinicaltrials.gov/study/NCT07227584
URL:https://assetmemo.bio/drug/methotrexate#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07768436-3826@assetmemo.bio
DTSTAMP:20261121T004007Z
DTSTART;VALUE=DATE:20300811
DTEND;VALUE=DATE:20300812
SUMMARY:Methotrexate: Phase 2 readout est. (NCT07768436)
DESCRIPTION:Methotrexate\, phase 2.\nStudy: A Study of Cyclophosphamide\, M
 ethotrexate\, Fluorouracil (CMF) for People With Breast Cancer\nEstimated 
 primary completion: 11 August 2030. This is a ClinicalTrials.gov estimate\
 , not a confirmed readout date\, and it can move.\nDrug page: https://asse
 tmemo.bio/drug/methotrexate#upcoming-events\nRegistry record: https://clin
 icaltrials.gov/study/NCT07768436
URL:https://assetmemo.bio/drug/methotrexate#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07228624-3826@assetmemo.bio
DTSTAMP:20261121T004007Z
DTSTART;VALUE=DATE:20300901
DTEND;VALUE=DATE:20300902
SUMMARY:Methotrexate: Phase 2 readout est. (NCT07228624)
DESCRIPTION:Methotrexate\, phase 2.\nStudy: Ruxolitinib Before\, During and
  After Hematopoietic Cell Transplant in Older Patients With Myelofibrosis 
 and Myelodysplastic Syndrome/Myeloproliferative Neoplasm Overlap Syndromes
 \nEstimated primary completion: 1 September 2030. This is a ClinicalTrials
 .gov estimate\, not a confirmed readout date\, and it can move.\nDrug page
 : https://assetmemo.bio/drug/methotrexate#upcoming-events\nRegistry record
 : https://clinicaltrials.gov/study/NCT07228624
URL:https://assetmemo.bio/drug/methotrexate#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07856069-3826@assetmemo.bio
DTSTAMP:20261121T004007Z
DTSTART;VALUE=DATE:20301031
DTEND;VALUE=DATE:20301101
SUMMARY:Methotrexate: Phase 2 readout est. (NCT07856069)
DESCRIPTION:Methotrexate\, phase 2.\nStudy: Arsenic Trioxide Combined With 
 Chemotherapy for Relapsed SHH-Activated and/or TP53-Mutant Medulloblastoma
 \nEstimated primary completion: October 2030. This is a ClinicalTrials.gov
  estimate\, not a confirmed readout date\, and it can move.\nDrug page: ht
 tps://assetmemo.bio/drug/methotrexate#upcoming-events\nRegistry record: ht
 tps://clinicaltrials.gov/study/NCT07856069
URL:https://assetmemo.bio/drug/methotrexate#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06128070-3826@assetmemo.bio
DTSTAMP:20261121T004007Z
DTSTART;VALUE=DATE:20301122
DTEND;VALUE=DATE:20301123
SUMMARY:Methotrexate: Phase 2 readout est. (NCT06128070)
DESCRIPTION:Methotrexate\, phase 2\, Acute Lymphoblastic Leukemia.\nStudy: 
 Ruxolitinib With Tacrolimus and Methotrexate for the Prevention of Graft V
 ersus Host Disease in Pediatric and Young Adult Patients Undergoing Alloge
 neic Hematopoietic Cell Transplant for Acute Myeloid Leukemia\, Acute Lymp
 hoblastic Leukemia\, or Myelodysplastic Syndrome\nEstimated primary comple
 tion: 22 November 2030. This is a ClinicalTrials.gov estimate\, not a conf
 irmed readout date\, and it can move.\nDrug page: https://assetmemo.bio/dr
 ug/methotrexate#upcoming-events\nRegistry record: https://clinicaltrials.g
 ov/study/NCT06128070
URL:https://assetmemo.bio/drug/methotrexate#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06124157-3826@assetmemo.bio
DTSTAMP:20261121T004007Z
DTSTART;VALUE=DATE:20301201
DTEND;VALUE=DATE:20301202
SUMMARY:Methotrexate: Phase 2 readout est. (NCT06124157)
DESCRIPTION:Methotrexate\, phase 2\, Acute Lymphoblastic Leukemia.\nStudy: 
 A Study Testing the Combination of Dasatinib or Imatinib to Chemotherapy T
 reatment With Blinatumomab for Children\, Adolescents\, and Young Adults W
 ith Philadelphia Chromosome Positive (Ph+) or ABL-Class Philadelphia Chrom
 osome-Like (Ph-Like) B-cell Acute Lymphoblastic Leukemia (B-ALL)\nEstimate
 d primary completion: 1 December 2030. This is a ClinicalTrials.gov estima
 te\, not a confirmed readout date\, and it can move.\nDrug page: https://a
 ssetmemo.bio/drug/methotrexate#upcoming-events\nRegistry record: https://c
 linicaltrials.gov/study/NCT06124157
URL:https://assetmemo.bio/drug/methotrexate#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06615050-3826@assetmemo.bio
DTSTAMP:20261121T004007Z
DTSTART;VALUE=DATE:20310117
DTEND;VALUE=DATE:20310118
SUMMARY:Methotrexate: Phase 3 readout est. (NCT06615050)
DESCRIPTION:Methotrexate\, phase 3.\nStudy: A Study of Tacrolimus/Methotrex
 ate/Ruxolitinib Versus Post-Transplant Cyclophosphamide/Tacrolimus/Mycophe
 nolate Mofetil in Non-Myeloablative/Reduced Intensity Conditioning Allogen
 eic Peripheral Blood Stem Cell Transplantation (BMT CTN 2203)\nEstimated p
 rimary completion: 17 January 2031. This is a ClinicalTrials.gov estimate\
 , not a confirmed readout date\, and it can move.\nDrug page: https://asse
 tmemo.bio/drug/methotrexate#upcoming-events\nRegistry record: https://clin
 icaltrials.gov/study/NCT06615050
URL:https://assetmemo.bio/drug/methotrexate#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07636564-3826@assetmemo.bio
DTSTAMP:20261121T004007Z
DTSTART;VALUE=DATE:20310416
DTEND;VALUE=DATE:20310417
SUMMARY:Methotrexate: Phase 2 readout est. (NCT07636564)
DESCRIPTION:Methotrexate\, phase 2\, Acute Lymphoblastic Leukemia.\nStudy: 
 Testing Blinatumomab With or Without Revumenib in Patients With B-cell Acu
 te Lymphoblastic Leukemia With a Genetic Change Requiring More Treatment\n
 Estimated primary completion: 16 April 2031. This is a ClinicalTrials.gov 
 estimate\, not a confirmed readout date\, and it can move.\nDrug page: htt
 ps://assetmemo.bio/drug/methotrexate#upcoming-events\nRegistry record: htt
 ps://clinicaltrials.gov/study/NCT07636564
URL:https://assetmemo.bio/drug/methotrexate#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07321912-3826@assetmemo.bio
DTSTAMP:20261121T004007Z
DTSTART;VALUE=DATE:20310601
DTEND;VALUE=DATE:20310602
SUMMARY:Methotrexate: Phase 2 readout est. (NCT07321912)
DESCRIPTION:Methotrexate\, phase 2.\nStudy: Eflornithine (DFMO) for Ewing S
 arcoma and Osteosarcoma\nEstimated primary completion: 1 June 2031. This i
 s a ClinicalTrials.gov estimate\, not a confirmed readout date\, and it ca
 n move.\nDrug page: https://assetmemo.bio/drug/methotrexate#upcoming-event
 s\nRegistry record: https://clinicaltrials.gov/study/NCT07321912
URL:https://assetmemo.bio/drug/methotrexate#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT02205762-3826@assetmemo.bio
DTSTAMP:20261121T004007Z
DTSTART;VALUE=DATE:20311130
DTEND;VALUE=DATE:20311201
SUMMARY:Methotrexate: Phase 2/3 readout est. (NCT02205762)
DESCRIPTION:Methotrexate\, phase 2/3.\nStudy: LCH-IV\, International Collab
 orative Treatment Protocol for Children and Adolescents With Langerhans Ce
 ll Histiocytosis\nEstimated primary completion: November 2031. This is a C
 linicalTrials.gov estimate\, not a confirmed readout date\, and it can mov
 e.\nDrug page: https://assetmemo.bio/drug/methotrexate#upcoming-events\nRe
 gistry record: https://clinicaltrials.gov/study/NCT02205762
URL:https://assetmemo.bio/drug/methotrexate#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07678229-3826@assetmemo.bio
DTSTAMP:20261121T004007Z
DTSTART;VALUE=DATE:20311231
DTEND;VALUE=DATE:20320101
SUMMARY:Methotrexate: Phase 3 readout est. (NCT07678229)
DESCRIPTION:Methotrexate\, phase 3.\nStudy: BRIDGE-NK: Immunotherapy Versus
  Chemotherapy Induction Followed by Autologous HSCT in Advanced NKTCL\nEst
 imated primary completion: 31 December 2031. This is a ClinicalTrials.gov 
 estimate\, not a confirmed readout date\, and it can move.\nDrug page: htt
 ps://assetmemo.bio/drug/methotrexate#upcoming-events\nRegistry record: htt
 ps://clinicaltrials.gov/study/NCT07678229
URL:https://assetmemo.bio/drug/methotrexate#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT03959085-3826@assetmemo.bio
DTSTAMP:20261121T004007Z
DTSTART;VALUE=DATE:20320331
DTEND;VALUE=DATE:20320401
SUMMARY:Methotrexate: Phase 3 readout est. (NCT03959085)
DESCRIPTION:Methotrexate\, phase 3\, Acute Lymphoblastic Leukemia.\nStudy: 
 Inotuzumab Ozogamicin and Post-Induction Chemotherapy in Treating Patients
  With High-Risk B-ALL\, Mixed Phenotype Acute Leukemia\, and B-LLy\nEstima
 ted primary completion: 31 March 2032. This is a ClinicalTrials.gov estima
 te\, not a confirmed readout date\, and it can move.\nDrug page: https://a
 ssetmemo.bio/drug/methotrexate#upcoming-events\nRegistry record: https://c
 linicaltrials.gov/study/NCT03959085
URL:https://assetmemo.bio/drug/methotrexate#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07387926-3826@assetmemo.bio
DTSTAMP:20261121T004007Z
DTSTART;VALUE=DATE:20330919
DTEND;VALUE=DATE:20330920
SUMMARY:Methotrexate: Phase 1/2 readout est. (NCT07387926)
DESCRIPTION:Methotrexate\, phase 1/2\, Acute Lymphoblastic Leukemia.\nStudy
 : Safety and Efficacy of Asciminib in Pediatrics and Young Adults With Rel
 apse/Refractory (r/r) Philadelphia Positive (Ph+) or ABL-class Ph-like Acu
 te Lymphoblastic Leukemia (ALL)\nEstimated primary completion: 19 Septembe
 r 2033. This is a ClinicalTrials.gov estimate\, not a confirmed readout da
 te\, and it can move.\nDrug page: https://assetmemo.bio/drug/methotrexate#
 upcoming-events\nRegistry record: https://clinicaltrials.gov/study/NCT0738
 7926
URL:https://assetmemo.bio/drug/methotrexate#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07724457-3826@assetmemo.bio
DTSTAMP:20261121T004007Z
DTSTART;VALUE=DATE:20331101
DTEND;VALUE=DATE:20331102
SUMMARY:Methotrexate: Phase 2/3 readout est. (NCT07724457)
DESCRIPTION:Methotrexate\, phase 2/3.\nStudy: Testing the Addition of a New
  Anti-Cancer Drug\, Glofitamab to Usual Chemotherapy for Burkitt and Doubl
 e Hit Lymphoma\nEstimated primary completion: 1 November 2033. This is a C
 linicalTrials.gov estimate\, not a confirmed readout date\, and it can mov
 e.\nDrug page: https://assetmemo.bio/drug/methotrexate#upcoming-events\nRe
 gistry record: https://clinicaltrials.gov/study/NCT07724457
URL:https://assetmemo.bio/drug/methotrexate#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06099366-3826@assetmemo.bio
DTSTAMP:20261121T004007Z
DTSTART;VALUE=DATE:20331231
DTEND;VALUE=DATE:20340101
SUMMARY:Methotrexate: Phase 2 readout est. (NCT06099366)
DESCRIPTION:Methotrexate\, phase 2\, Acute Lymphoblastic Leukemia.\nStudy: 
 Treatment of Newly Diagnosed Standard Risk Acute Lymphoblastic Leukemia in
  Children\nEstimated primary completion: 31 December 2033. This is a Clini
 calTrials.gov estimate\, not a confirmed readout date\, and it can move.\n
 Drug page: https://assetmemo.bio/drug/methotrexate#upcoming-events\nRegist
 ry record: https://clinicaltrials.gov/study/NCT06099366
URL:https://assetmemo.bio/drug/methotrexate#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06289673-3826@assetmemo.bio
DTSTAMP:20261121T004007Z
DTSTART;VALUE=DATE:20340531
DTEND;VALUE=DATE:20340601
SUMMARY:Methotrexate: Phase 4 readout est. (NCT06289673)
DESCRIPTION:Methotrexate\, phase 4\, Acute Lymphoblastic Leukemia.\nStudy: 
 Identification of Necessary Information for Treatment Induction in Newly D
 iagnosed Acute Lymphoblastic Leukemia/Lymphoma\nEstimated primary completi
 on: May 2034. This is a ClinicalTrials.gov estimate\, not a confirmed read
 out date\, and it can move.\nDrug page: https://assetmemo.bio/drug/methotr
 exate#upcoming-events\nRegistry record: https://clinicaltrials.gov/study/N
 CT06289673
URL:https://assetmemo.bio/drug/methotrexate#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06085742-3826@assetmemo.bio
DTSTAMP:20261121T004007Z
DTSTART;VALUE=DATE:20340930
DTEND;VALUE=DATE:20341001
SUMMARY:Methotrexate: Phase 2 readout est. (NCT06085742)
DESCRIPTION:Methotrexate\, phase 2.\nStudy: BRE-08 Phase II Study of CMC Re
 gimen for Early Stage Breast Cancer\nEstimated primary completion: Septemb
 er 2034. This is a ClinicalTrials.gov estimate\, not a confirmed readout d
 ate\, and it can move.\nDrug page: https://assetmemo.bio/drug/methotrexate
 #upcoming-events\nRegistry record: https://clinicaltrials.gov/study/NCT060
 85742
URL:https://assetmemo.bio/drug/methotrexate#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT05535166-3826@assetmemo.bio
DTSTAMP:20261121T004007Z
DTSTART;VALUE=DATE:20350731
DTEND;VALUE=DATE:20350801
SUMMARY:Methotrexate: Phase 2 readout est. (NCT05535166)
DESCRIPTION:Methotrexate\, phase 2.\nStudy: Molecular and Clinical Risk-Dir
 ected Therapy for Infants and Young Children With Newly Diagnosed Medullob
 lastoma\nEstimated primary completion: July 2035. This is a ClinicalTrials
 .gov estimate\, not a confirmed readout date\, and it can move.\nDrug page
 : https://assetmemo.bio/drug/methotrexate#upcoming-events\nRegistry record
 : https://clinicaltrials.gov/study/NCT05535166
URL:https://assetmemo.bio/drug/methotrexate#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07072585-3826@assetmemo.bio
DTSTAMP:20261121T004007Z
DTSTART;VALUE=DATE:20350901
DTEND;VALUE=DATE:20350902
SUMMARY:Methotrexate: Phase 2/3 readout est. (NCT07072585)
DESCRIPTION:Methotrexate\, phase 2/3\, Acute Lymphoblastic Leukemia.\nStudy
 : Testing the Addition of Daratumumab to Chemotherapy for Treating Patient
 s With Newly-Diagnosed T-Cell Lymphoblastic Leukemia (T-ALL) and T-Cell Ly
 mphoblastic Lymphoma (T-LL)\nEstimated primary completion: 1 September 203
 5. This is a ClinicalTrials.gov estimate\, not a confirmed readout date\, 
 and it can move.\nDrug page: https://assetmemo.bio/drug/methotrexate#upcom
 ing-events\nRegistry record: https://clinicaltrials.gov/study/NCT07072585
URL:https://assetmemo.bio/drug/methotrexate#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT05725200-3826@assetmemo.bio
DTSTAMP:20261121T004007Z
DTSTART;VALUE=DATE:20381231
DTEND;VALUE=DATE:20390101
SUMMARY:Methotrexate: Phase 2 readout est. (NCT05725200)
DESCRIPTION:Methotrexate\, phase 2.\nStudy: Study to Investigate Outcome of
  Individualized Treatment in Patients With Metastatic Colorectal Cancer\nE
 stimated primary completion: 31 December 2038. This is a ClinicalTrials.go
 v estimate\, not a confirmed readout date\, and it can move.\nDrug page: h
 ttps://assetmemo.bio/drug/methotrexate#upcoming-events\nRegistry record: h
 ttps://clinicaltrials.gov/study/NCT05725200
URL:https://assetmemo.bio/drug/methotrexate#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
END:VCALENDAR
